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The Idea behind the Study 
The idea behind the study described in this thesis arose from a bibliographic research concerning the 
biological behavior of several compounds present in different extracts of Chelidonium majus (C. majus), a herb 
widely diffused in several areas around the world. This herb is used, according to an unwritten knowledge, in 
the folk medicine of Northern Sardinia (Italy) both for healing severe burns and wounds, and for reducing 
scars. 
The interest toward this herb was initially motivated by the observation that different properties of some of its 
extracts are apparently in contrast with each other. Indeed the ability of stimulating proliferation and migration 
of different cell types have been found as well as inhibitory properties. These latter properties are mostly 
evident in different cancer cell lines. 
The bibliographic research afforded a great variety of data concerning a very wide spectrum of activities 
possessed by the extacts of C. majus and many of their single components. Such biological properties range 
from antimicrobial to immunostimulating as well as keratolytic and anticancer activity, other than stimulating 
activity of proliferation and/or migration of several cell types. 
In particular our interest was kept by the description of a semisynthetic derivative (Ukrain) never approved by 
the FDA for which, nevertheless, anticancer and antimetastatic properties are reported by a quite high number 
of scientific publications. Ukrain is based on a particular C. maius extract added with a chemical reactant. 
The study described here started with the identification of one among the many biological targets potentially 
involved in the anticancer-antimetastatic activity of Ukrain. 
Among the compounds contained in C. majus, a single-chain protein (chelidocistatin) is described to inhibit 
Catehpsin L, which has been recognized to be an interesting target for anticancer-antimetastatic agents. 
Moreover several alkaloids present in C. majus have been recognized to possess anticancer activity: among 
them Chelidonine is reported to interfere with the dynamic tubulin polymerization-depolymerization equilibrium 
and to produce cell cycle arrest in different cell lines. 
After a first screening of the literature data, Cathespin L and tubulin appeared to be optimal targets for the 
design of new effective anticancer drugs and Cathepsin L was selected as the first target to be considered. It 
became the primary target to be addressed in the search of new anticancer drugs described in in this thesis.  
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CHAPTER 1 
ENZYME AND PROTEOLYSIS 
 
              
 
This chapter briefly describes the proteolysis, the relevant types of protease and their regulation. The 
maintenance of a healthy organism largely relies upon controlled biosynthesis, maturation, function and 
terminal breakdown of proteins. Proteolytic enzymes contribute to these process by irreversibly cleaving 
peptide bonds. In particular the lysosomal proteins are important for these processes because of their high 
proteolytic activity. 
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1.1 Basics on Enzyme Kinetics 
Life depends on the existence of powerful and specific catalysts: the enzymes. Almost every biochemical 
reaction is catalyzed by an enzyme. Enzymes, like other proteins, have molecular weights ranging from about 
12,000 to more than 1 million Da. Some enzymes do not require, other than the chemical functionalities of 
their amino acid residues, any additional chemical species for exerting their activity on the molecules to be 
acted upon. Others require an additional chemical component called cofactor — either one or more inorganic 
ions, such as Fe2+, Mg2+, Mn2+, or Zn2+, or a complex organic or metal-organic molecule called a coenzyme. 
Some enzymes require both a coenzyme and one or more metal ions for their activity. A coenzyme or metal 
ion that is very tightly or even covalently bound to the enzyme protein is called a prosthetic group. A complete, 
catalytically active enzyme together with its bound coenzyme and/or metal ions is called a holoenzyme. The 
protein moiety of such an enzymatic complex is called the apoenzyme or apoprotein. Many enzymes have 
been named by adding the suffix “-ase” to the name of their substrate or to a word or phrase describing their 
activity. Thus urease catalyzes hydrolysis of urea, and DNA polymerase catalyzes the polymerization of 
nucleotides to form DNA. Other enzymes were named based on the first discover of a broad function, before 
the specific reaction catalyzed was known.The enzymatic catalysis of reactions is essential to living systems. 
Under biologically relevant conditions, uncatalyzed reactions tend to be slow—most biological molecules are 
quite stable at the neutral-pH, mild-temperature, aqueous environment inside cells. Furthermore, many 
common reactions in biochemistry entail chemical events that are unfavorable or unlikely in the cellular 
environment, such as the transient formation of unstable charged intermediates or the collision of two or more 
molecules in the precise orientation required for reaction. Reactions required to digest food, send nerve 
signals, or contract a muscle simply do not occur at a useful rate without catalysis. An enzyme circumvents 
these problems by providing a specific environment within which a given reaction can occur more rapidly. The 
distinguishing feature of an enzyme-catalyzed reaction is that it takes place within the confines of a pocket on 
the enzyme called the active site (Figure 1). The molecule that is bound in the active site and is acted upon by 
the enzyme is called the substrate.  
                                                             
Figure 1. Binding of a substrate to an enzyme at the active site. 
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A simple enzymatic reaction might be modeled by the following scheme: 
 
                                               E +S            ES           EP           E+P                
 
where E, S, and P represent the enzyme, the substrate, and the product respectively. ES and EP are transient 
complexes of the enzyme with the substrate and with the product. To understand catalysis, we must first recall 
the important distinction between reaction equilibria and reaction rates. The function of a catalyst is to increase 
the rate of a reaction. Catalysts do not affect reaction equilibria. Any reaction, such as “S to P”, can be 
described by a reaction coordinate diagram (Figure 2), a picture of the energy changes during the reaction. 
The modern notion of enzymatic catalysis, first proposed by Michael Polanyi (1921) and Haldane (1930), was 
subsequently enriched by Linus Pauling in 1946: in order to catalyze reactions, an enzyme must be 
complementary to the reactants transition state. This means that optimal interactions between substrate and 
enzyme occur only in the transition state. Figure 6–5c demonstrates how such an enzyme can work. Many of 
these interactions involve parts of the stick that are distant from the point of breakage; thus interactions 
between the stickase and nonreacting parts of the stick provide some of the energy needed to catalyze stick 
breakage. This “energy payment” translates into a lower net activation energy and a faster reaction rate.  
The reaction catalysed by an enzyme uses exactly the same reactants and produces exactly the same 
products as the uncatalysed reaction. Like other catalysts, enzymes do not alter the position of equilibrium 
between substrates and products.[1] However, unlike uncatalysed chemical reactions, enzyme-catalysed 
reactions display saturation kinetics. For a given enzyme concentration and for relatively low substrate 
concentrations, the reaction rate increases linearly with substrate concentration; the enzyme molecules are 
largely free to catalyse the reaction, and increasing substrate concentration means an increasing rate at which 
the enzyme and substrate molecules encounter one another. However, at relatively high substrate 
concentrations, the reaction rate asymptotically approaches the theoretical maximum; the enzyme active sites 
are almost all occupied and the reaction rate is determined by the intrinsic turnover rate of the enzyme. The 
substrate concentration midway between these two limiting cases is denoted by KM. The two most important 
kinetic properties of an enzyme are how quickly the enzyme becomes saturated with a particular substrate, 
and the maximum rate it can achieve. 
A particularly impressing picture of the key-lock mechanism is represented in figure 2  
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Figure 2. An imaginary enzyme (stickase) designed to catalyze breakage of a metal stick. (a) Before the stick is broken, it must first be bent (the 
transition state). In both stickase examples, magnetic interactions take the place of weak bonding interactions between enzyme and substrate. (b) A 
stickase with a magnet-lined pocket complementary in structure to the stick (the substrate) stabilizes the substrate. Bending is impeded by the 
magnetic attraction between stick and stickase. (c) An enzyme with a pocket complementary to the reaction transition state helps to destabilize the 
stick, contributing to catalysis of the reaction. The binding energy of the magnetic interactions compensates for the increase in free energy required 
to bend the stick. Reaction coordinate diagrams (right) show the energy consequences of complementarity to substrate versus complementarity to 
transition state (EP complexes are omitted). _GM, the difference between the transition-state energies of the uncatalyzed and catalyzed reactions, 
is contributed by the magnetic interactions between the stick and stickase. When the enzyme is complementary to the substrate (b), the ES 
complex is more stable and has less free energy in the ground state than substrate alone. The result is an increase in the activation energy. 
The knowledge of these properties suggests what an enzyme might do in the cell and enable the researchers 
to predict how the enzyme will respond to changes in these conditions. Enzyme assays are laboratory 
procedures that measure the rate of enzyme reactions. Because enzymes are not consumed by the reactions 
they catalyze, enzyme assays usually follow changes in the concentration of either substrates or products to 
measure the rate of reaction. There are many methods of measurement. Spectrophotometric assays observe 
change in the absorbance of light between products and reactants; radiometric assays involve the 
incorporation or release of radioactivity to measure the amount of product made over time. Spectrophotometric 
assays are most convenient since they allow the rate of the reaction to be measured continuously. Although 
radiometric assays require the removal and counting of samples (i.e., they are discontinuous assays) they are 
usually extremely sensitive and can measure very low levels of enzyme activity.[2] An analogous approach is to 
use mass spectrometry to monitor the incorporation or release of stable isotopes as substrate is converted into 
product. The most sensitive enzyme assays use lasers focused through a microscope to observe changes in 
single enzyme molecules as they catalyse their reactions. These measurements either use changes in the 
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fluorescence of cofactors during an enzyme's reaction mechanism, or of fluorescent dyes added onto specific 
sites of the protein to report movements that occur during catalysis.[3] These studies are providing a new view 
of the kinetics and dynamics of single enzymes, as opposed to traditional enzyme kinetics, which observes the 
average behaviour of populations of millions of enzyme molecules.[4][5] 
An example of progress curve for an enzyme assay is shown in Figure 3. The enzyme produces product at an 
initial rate that is approximately linear for a short period after the start of the reaction. As the reaction proceeds 
and substrate is consumed, the rate continuously slows (so long as substrate is not still at saturating levels). 
To measure the initial (and maximal) rate, enzyme assays are typically carried out while the reaction has 
progressed only a few percent towards total completion. The length of the initial rate period depends on the 
assay conditions and can range from milliseconds to hours. However, equipment for rapidly mixing liquids 
allows fast kinetic measurements on initial rates of less than one second.[6] These very rapid assays are 
essential for measuring pre-steady-state kinetics. Most enzyme kinetics studies concentrate on this initial, 
approximately linear part of enzyme reactions. However, it is also possible to measure the complete reaction 
curve and fit this data to a non-linear rate equation. This way of measuring enzyme reactions is called 
progress-curve analysis.[7] This approach is useful as an alternative to rapid kinetics when the initial rate is too 
fast to be accurately measured. 
 
                                         
 
Figure 3. Progress curve for an enzyme reaction. The slope in the initial rate period is the initial rate of reaction v. The Michaelis–Menten 
equation describes how this slope varies with the concentration of substrate. 
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1.1 General characteristics of the proteases 
Proteases are enzymes present in all tissues that hydrolyze peptide bonds. Other than determining the 
ultimate fate of the proteins, in many cases, their activity is involved in the regulation of cellular functions, 
achieved through the activation or inactivation of enzymatic proteins. Although the proteolysis is required for 
the life of cells, for the maintenance of an optimal balance between synthesis and degradation of proteins, it is 
undeniable that an excessive activity of proteases is at the basis of many pathologies and cell death, 
depending upon the response to physiological or pathological stimuli. 
The complete degradation of the proteins in the constituent amino acids takes place for a large part inside the 
cells and, in physiological conditions, it is in perfect balance with protein synthesis. In addition to this form of 
“full” proteolysis, different cases of “limited” proteolysis take place both intracellularly and extracellularly. In 
these latter cases the protease, acting on specific sites of hydrolysis, cause the cleavage of the target protein 
into one or more peptide fragments This type of proteolysis can be classified as a post-translational 
modification. However, unlike other covalent modifications of proteins (eg phosphorylation), proteolysis is 
irreversible. The proteolysis is therefore at the basis of irreversible processes such as formation of cytokines, 
hormones and neuro-peptides, as well as coagulation, and apoptosis.[8]. 
1.2   Classification and Naming of Protease 
The hydrolysis of the peptide bond is an acid-base reaction which starts with the attack of a nucleophilic group 
of the enzyme active site on the carbon atom of the peptide bond carbonyl. 
Proteases are classified according to two criteria [9]: 
a) The type of catalyzed reaction.  
b) The chemical nature of the catalysis site. 
The classification criterion base on the type of catalyzed reaction is the one generally used to classify the 
enzymes. The proteases, in their entirety, constitute a sub-class of hydrolases named as sub-class 4 which in 
turn belongs to the so-called class 3 of hydrolases (3.4 sub-class). The further splitting of the 3.4 sub-class in 
two sub-sub-classes, exopeptidases (CEs 3.4.1n) and endopeptidases or proteinases (CEs 3.4.2n), is made in 
relation to the site of hydrolysis (Figure 1). The suffix endo-is used for those enzymes that act of preference on 
amino acid residues distant from the ends: in special conditions the endopeptidase can behave as 
exopeptidases. A particular subgroup of endopeptidase (oligopeptidase) is represented by shorter polypeptide 
chain fragments (<50 residues). The exopeptidases act near the ends of the polypeptide chain. If it is 
seconded to the N-terminal residue the name is “amino peptidase” (EC 3.4.11), while for the detachment of the 
last two or three residues at this end we use respectively the terms of dipeptidyl-and tripeptidil-peptidase (EC 
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3.4.14 ). If the last two residues are located on the side of the carboxy terminus the name is peptidyl-
dipeptidase (EC 4.3.15). The amino acid names are recalled in the ending-part of the amino-peptidase protein 
names so that they are recognized on the basis of the specific peptide bond which they are able to cleave. 
 
                   Endopeptidase                                                Exopeptidase                                                  Exopeptidase      
                                                                                       (aminopeptidase)                                           (carboxypeptidase) 
 
 
 Figure 4. Modes of substrate cleavage caused by peptidases (cysteine cathepsins were used as examples): endopeptidase (cathepsin L) and 
exopeptidases (left, cathepsin H, an aminopeptidase; and right, cathepsin X, a carboxypeptidase). Peptide substrate (schematically represented by 
cyan balls) runs through the entire length of the active site of an endopeptidase framework (blue) and is cleaved in the middle of the molecule 
(scissile bond marked yellow). In exopeptidases, substrate binding is structurally constrained (mini-chain in cathepsin H, orange; mini-loop in 
cathepsin X, green). In cathepsin exopeptidases these additional structural elements also provide negative charge (cathepsin H) to bind the 
positively charged amino terminus (blue) of the substrate, or positive charge (cathepsin X) to bind the negatively charged carboxyl terminus (red) of 
the substrat [9] . 
 
 
The classification criterion base on the different types of nucleophilic attack implies that the proteases are 
grouped into four main classes: Serine, Cysteine, Aspartic and Metal (in most cases Zn2+) protease: (Figure 5). 
In the last two classes, the aspartic acid moiety or the metal ion polarize a water molecule, so that the oxygen 
atom can act as nucleophile species. In the other classes instead the nucleophile is represented by the serine 
oxydril in the form of oxyanion, or from the of cysteine sulfhydryl in the form of thiolate (Figure 6). 
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Figure5. Classification of proteolytic enzyme[8]. 
 
Due to their relevance both as therapeutic targets and probe molecules for basic research, the discovery of 
new protease inhibitors is briskly pursued at present. Inhibitors may help in the isolation and characterization 
of the different types of proteases.  
 
                     
 
Figura 6. Catalytic mechanisms of mammalian proteases. The five major catalytic classes of proteases use two fundamentally different catalytic 
mechanisms to stabilize the tetrahedral intermediate. In the serine, cysteine and threonine proteases the nucleophile of the catalytic site is part of 
an amino acid (covalent catalysis), whereas in the metalloproteinases and aspartic proteases the nucleophile is an activated water molecule (non-
covalent catalysis). In covalent catalysis, histidines normally function as a base, whereas in non-covalent catalysis Asp or Glu residues and zinc 
(metalloproteinases) serve as acids and bases. A further difference between the two groups is apparent in the formation of the reaction products 
from the tetrahedral intermediate, which for cysteine and serine proteases requires an additional intermediate step (acyl-enzyme intermedia)[9] 
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1.3   Characteristics and Regulation of Intracellular Proteolysis.  
In the cell the complete degradation of proteins is carried out by lysosomal enzymes and proteasome. The first 
ones serve primarily to remove proteins from the extracellular and intracellular vesicles, while some of the 
intracellular proteins are degraded by the proteasome. The two intracellular processes require, unlike the 
extracellular system, the availability of ATP. The lysosomal degradation uses ATP to acidify the vesicles 
through a proton pump, while the degradation by proteasome requires ATP at the level of poly-ubiquitination of 
the substrate and the subsequent demolition. The proteolysis in general, and in particular the intracellular one, 
must be subject to a tight spatial and temporal control to avoid the indiscriminate protein degradation which 
would lead in a short time to the destruction of the tissues. 
 
Several factors are involved in the regulation of the intracellular proteolysis [10]: 
 
 Compartmentalisation. Is the main response of the cell to the need to safeguard their structure. In 
addition, the compartmentalization of more enzymes participating in the same metabolic process 
facilitates the exchange of substrates and considerably increases the overall speed of the process. In 
this regard those processes of post-translational modification of the proteins that determine the 
addressing and activation become particularly important.  
 
 Conversion of zymogens. The proteases are generally synthesized in the form of inactive precursors 
(zymogens) that are activated through appropriate proteolysis. Proteolysis must be so strictly 
controlled, being the limiting step of the related proteolytic processes. Indeed, the zymogen-enzyme 
conversion usually takes place in specific conditions (e.g. at acidic pH), or in response to specific 
signals that may originate inside or outside the cell. 
 
 pH.  Several proteases are poorly active at neutral pH, being optimized to operate in the acidic 
compartments (lysosomes and endosomes). In such sites the partial denaturation of the substrates, 
determined by the low pH, favors the proteolytic activity. 
 
 Redox State. In cysteine proteases the thiol group is readily oxidizable: because of that, this kind of 
enzymes require a reducing environment which is ensured in the endosomes by the accumulation of 
cysteine. 
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 Endogenous inhibitors. The activities of several intracellular proteases, the cytoplasmic protease in 
particular, are controlled by their equilibrium with endogenous inhibitors which are mostly of peptidic 
nature. They are generally present in large excess with respect to the enzyme. This is without doubt 
the more selective regulatory mechanism in the cell. There are several known serine proteases 
inhibitors of proteic type, comprised in the serpin family, located mostly in the extracellular 
environment. The most common protein inhibitors of cysteine proteases within the group are splitted 
into three families of cystatins. The oligomeric proteins comprised in family 1 are localized in the 
cytoplasm, while the members of other families are present in the extracellular compartment. The 
reversible, competitive inhibition is directed mainly to the papain-like proteases. The activity of Calpain 
is specifically inhibited by Calpastatin, whereas Caspases are inhibited by both endogenous proteins, 
and exogenous proteins introduced by infectious agents. Up to now no endogenous inhibitors of 
aspartic and metal proteases are known. This may explain, at least in part, the high pathogenicity of 
some infectious agents[11]. 
 
In addition to protein catabolism, the degradation of intracellular proteins plays a significant biochemical and 
physiological role completely different in the case of limited proteolysis, that is realized not only in the 
conversion of zymogens to active forms, but also in the formation of new enzymes or peptides with different 
and specialized functions compared to those of the native protein. In general the proteases may participate in 
the processes of transduction of the signal at three levels [12]:  
 
a) Activation of a specific way of signal transduction. Following the appearance of a second messenger 
(Ca2+ for example), or the interaction with a specific effector protein, the intracellular proteolysis is 
activated to trigger in turn a cascade of other enzymatic activities determinants for the cellular 
response. 
 
b) Modulation of the activity of the receptors. The proteolysis of the intracellular domain of these trans-
membrane proteins can activate or repress specific receptors. 
 
c) Regulation of the number of receptors. A membrane receptor, internalized by endocytosis, can be 
recycled to the membrane or degraded in lysosomes. The number of receptors is given by this 
balance. 
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1.4   The Lysosome 
Lysosomes are membrane-delimited organelles which occur in all mammalian cells except red blood cells. 
Lysosomes are defined by functional rather than structural properties. They contain a high proton 
concentration (pH ≤ 5) and more than 40 hydrolases with an optimal H below 6. Their limiting membrane is 
endowed with specific integral proteins including a vacuolar-type H+-ATPase, several highly glycosylated 
proteins and various types of transporters. Lysosomes are engaged in the degradation of macromolecules 
delivered from the cell‘s own cytoplasm as well as materials taken up from the extracellular space (by 
endocytosis). Depending on the cell type and the functional state, lysosomes can considerably vary in 
structure. Therefore it is not surprising that the existence of lysosomes was first realized solely on the basis of 
biochemical results. The term lysosome was coined by DeDuve five decades ago[13]. Only thereafter, 
ultrastructural and enzyme-cytochemical studies of Novikoff and coworkers[14] uncovered the morphologic 
identity of lysosomes. Expanding research in this field gradually revealed the lysosomes as being part of the 
highly dynamic endosome/lysosome system (Figure 7), a collection of several categories of vesicular 
organelles which, to a certain extent, exchange membrane constituents and contents thus having overlapping 
properties. An important feature of lysosomes which serves to discriminate them from endosomes and other 
related vesicles is the absence of mannose-6-phosphate receptors.  
 
1.5   Biogenesis of Lysosomes  
On the basis of the subcellular distribution of acid phosphatase, as demonstrated by enzyme cytochemistry, 
Novikoff and coworkers[15] proposed the concept of GERL (Golgi apparatus - endoplasmic reticulum - 
lysosome). It implied (a) that lysosomal enzymes, after biosynthesis in the rough endoplasmic reticulum (ER), 
are packaged into vesicles (“primary lysosomes”) budding off from tubules which are continuous with the ER 
and intimately related to the Golgi apparatus, (b) that the vesicles are conveyed to preexisting lysosomes 
which have already been engaged in a digestive process (“secondary lysosomes”). This concept was later 
replaced by the concept of the trans Golgi network (TGN) as the common exit site for all products including 
lysosomal enzymes, secretory proteins and membrane proteins[16]. The most important modifications of the 
previous GERL concept were induced by data indicating that the intracellular transport of lysosomal enzymes 
is receptor-mediated and has to pass through a prelysosomal compartment (Figure 7). 
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Figure 7.  Diagrammatic summary of the endosome/lysosome system, with special reference to the biogenesis of lysosomes. After synthesis in 
the rER and modification in the Golgi apparatus (not shown) precursors of soluble lysosomal enzymes decorated with mannose-6-phosphate 
residues meet the mannose-6-phosphate receptor (MPR) in the trans Golgi network (TGN), are packaged (1) into clathrin-coated vesicles (ccv), 
and are transported (2) to late endosomes (LE) either directly or indirectly via early endosomes (EE) (3). The process of enzyme transfer (4) from 
the LE to the lysosome (Lys) is not fully elucidated yet; possibly LE matures to become Lys, or LE and Lys fuse to form a transient hybrid organelle 
(for further possibilities see text). The MPR is recycled (5) from the LE to the TGN, the lysosome is devoid of MPRs. A minor portion of the enzyme 
precursors gets into the secretory pathway (6) and is recaptured into clathrin-coated pits (ccp) by MPRs, which may be transferred (7) from the EE 
to the plasma membrane. Thus the enzyme precursors can reach the lysosome via the endocytic pathway (8) as do endocytic tracer molecules (9), 
whose receptors are recycled from the tubular extensions of the EE (10). Autophagic vacuoles (AV) and phagocytic vacuoles (PV) acquire 
lysosomal enzymes by fusion with lysosomes and/or LE (11) to become autolysosomes and phagolysosomes,85 respectively. LE often resemble 
multivesicular bodies, i.e., they display invaginations of their membrane and internal vesicles budded off the invaginations (or representing cross 
sections of the invaginations). lgp/lamp, lysosomal membrane glycoproteins/lysosome-associated membrane proteins[9]. 
 
1.5   Transport of Lysosomal Enzymes 
More than 50 acid hydrolases involved in the ordered lysosomal degradation of a variety of proteins, lipids, 
carbohydrates, and nucleic acids have been identified. The hydrolases are enclosed by a membrane 
containing a set of highly glycosylated lysosomal membrane proteins. Lysosomal enzymes are also 
components of cell type-specific compartments referred to as lysosome-related organelles which include 
melanosomes, lytic granules, MHC class II compartments, platelet-dense granules, and synaptic-like 
microvesicles.1 The biogenesis of new lysosomes or lysosome-related organelles requires a continuous 
substitution with newly synthesized components. The targeting of acid hydrolases depends on the presence of 
mannose 6-phosphate (M6P) residues that are recognized by specific receptors mediating the intracellular 
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transport to an endosomal/prelysosomal compartment. The acidification of endosomes, lysosomes, and 
lysosome-related organelles facilitates not only the dissociation of the receptor-ligand complexes, but also the 
proteolytic processing required for the enzymatic activation of several hydrolases as well as the denaturation 
of target proteins as prerequisite for lysosomal proteolysis[17] . 
 
1.5.1  Synthesis and Modifications of Soluble Lysosomal Proteins 
Lysosomal hydrolases are synthesized with an N-terminal sequence of 20-25 amino acids recognized by the 
signal recognition particle which enables the nascent polypeptides to be translocated across the membrane of 
the endoplasmic reticulum (ER, Figure 8, step 1). After removal of the signal peptide by a signal peptidase, 
preformed oligosaccharides are transferred to certain asparagine residues which are part of an N-glycosylation 
consensus motif Asn-X-Thr/Ser[18]. Typically, the oligosaccharides are composed of 3 glucose, 9 mannose and 
2 N-acetylglucosamine residues (Glc3Man9GlcNac2). The oligosaccharides undergo extensive processing 
before completion of translation by removal of the outmost glucose residues catalyzed by glucosidase I and II. 
Monoglycosylated core glycans of the newly synthesized polypeptide then bind to the molecular chaperone 
calnexin until the protein is properly folded[19].  Furthermore, all members of the sulfatase family responsible for 
the hydrolysis of sulfate esters from sulfated mono- and polysaccharides, glycolipids and hydroxysteroids, are 
modified in the ER generating a Cα-formylglycine (FGly) residue. The oxidation of a highly conserved cysteine 
occurs when the protein has not been folded yet and is catalyzed by the FGly-generating enzyme (FGE). 
Mutations in the gene encoding the human FGE result in the appearance of multiple lysosomal sulfatases 
lacking enzymatic activity[20]. Moreover, aspartylglucosaminidase, a lysosomal enzyme that hydrolyzes the 
amide bond between asparagines and N-acetylglucosamine, has been reported to be rapidly activated in the 
ER by a proteolytic cleavage of the inactive precursor into α- and β-subunits which is triggered by the 
dimerization of the two precursor molecules[21]. 
 
1.5.2  Formation of Mannose 6-Phosphate Recognition Marker 
Upon arrival in the Golgi, the oligosaccharide chains of lysosomal enzymes are further trimmed and modified 
by the addition of complex sugar residues (galactose, fucose, and sialic acid), sulphate groups, and by the 
formation of the M6P recognition marker. This marker is generated by the sequential action of two enzymes 
[22]. In the first step, GlcNac-1-phosphate is added to the C6-hydroxyl group of selected mannoses on high 
mannose-type oligosaccharides by the enzyme UDP-N-acetylglucosamine: lysosomal enzyme N-
acetylglucosamine-1-phosphotransferase (phosphotransferase) (Figure 8, step 2). The purified bovine 
phosphotransferase is a 540 kDa heterohexameric complex composed of two disulfide-linked homodimer of 
166 and 51 kDa subunits and two noncovalently associated 56 kDa subunits (α2β2γ2)[23,24].  
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Figure 5. Model for the intracellular transport of MPR and proteins to lysosomes. Soluble lysosomal enzymes are synthesized and translocated 
into the lumen of the ER (step 1). In the Golgi (step 2) the enzymes are equipped with the M6P recognition marker (step 3) followed by binding to 
MPRs. The receptor-ligand complexes are transported to the early endosomal compartment (EE; step 4). Due to the low pH the receptor-ligand 
complexes dissociate and the lysosomal enzymes are delivered to the lysosome (Lys, steps 5 and 6). The MPRs recycle either back to the TGN 
(steps 7 and 8) or to the plasma membrane (step 9). Exogenous M6P-containing proteins can be internalized by CI-MPR (step 10) and are 
transported to lysosomes along the endocytic pathway (step 11). Lysosomal enzymes escaping binding to MPR in the TGN are secreted (step 
12)[12]. 
 
The phosphotransferase γ-subunit has been shown to form cysteine-linked dimers and contains two N-linked 
oligosaccharide. It has been proposed that the α and β-subunits harbour phosphotransferase activity and the 
γ-subunit functions in recognition of lysosomal enzymes. Studies with chimeric proteins between cathepsin D 
and pepsinogen, mutant cathepsin L and aspartylglucosaminidase, and blocking antibodies against various 
epitopes on arylsulfatase A suggest that 2-3 lysine residues, separated by a distance of ~ 34 Å residing in 
distinct regions of the enzymes, are critical phosphorylation signals[25,26]. In the second step, N-
acetylglucosamine residues are removed by an N-acetylglucosamine-1-phosphodieste α-N-
acetylglucosaminidase (UCE; uncovering enzyme) exposing the M6P recognition marker (Figure 4, step 3). 
The human UCE is a type I membrane spanning glycoprotein of 515 amino acids with a transmembrane 
domain and a cytoplasmic tail of 41 amino acids. UCE is mainly localized in the TGN and constitutively cycles 
via the plasma membrane[27] UCE is synthesized as an inactive proenzyme which is activated in the TGN by 
Chapter 1 
Page 16 
 
the cleavage of an N-terminal pro-peptide catalyzed by the endoprotease furin The bovine UCE exists as a 
tetramer composed of two disulfide-linked homodimers with molecular masses of 68 kDa for each monomer[28]. 
Following the uncovering of the M6P marker, lysosomal enzymes can be recognized by mannose 6-phosphate 
receptors (MPRs). 
 
1.5.3  Mannose 6-Phosphate Receptors 
In mammalian cells two MPR exist, one is a 46 kDa cation-dependent (CD-MPR, MPR46) and the other an 
300 kDa cation-independent (CI-MPR, MPR300) protein[29]. Both MPRs are type I membrane glycoproteins 
that differ in their developmental expression pattern, subcellular localization, quarternary structure, half life of 
receptor protein, ligand binding properties and functions[30]. The MPRs bind mono- or diphosphorylated 
oligosaccharides with a Kd of 2 x 10-7 -2 x 10-9 M per mole of receptor. Subsequently the receptor-ligand 
complexes exit from the TGN in clathrin-coated vesicles and fuse with membranes of the early or late 
endosomal compartment (Figure 8, steps 4, 5). Due to the low pH, the lysosomal enzymes dissociate and are 
delivered to lysosomes (Figure 8, step 6); the MPRs recycle back to the TGN to mediate further rounds of 
transport (Figure 8, steps 7, 8)[29]. Small amounts of both MPRs are localized at the plasma membrane (Figure 
4, step 10) but only the CI-MPR is capable of binding and internalizing M6P-containing lysosomal enzymes 
(Figure 8, step 11). 
 
1.6 The Lysosomal Proteases 
Lysosomal proteolytic enzymes catalyze the hydrolysis of proteins. Only few of the proteinases work as amino- 
or carboxypeptidases, while most are endopeptidases preferably cleaving peptide bonds within a polypeptide 
chain rather than at its ends. Accordingly, the name cathepsin, derived from the Ancient Greek word καθέψω 
(kathépsō,“boil down”), was originally meant to be reserved for endopeptidases. However, it turned out that 
cathepsin Bl which, to follow this convention, was explicitly named as such, is both, an endo- and an 
exopeptidase. In the late 1990s, a more recent nomenclature discussion was started by members of the 
International Proteolysis Society (www.protease.org). Due to the progress in genome sequencing, the 
scientific community was afraid of shortly running out of letters of the alphabet to be added to the term 
cathepsin in order to name newly identified enzymes. However, no better nomenclature system was found, 
and, hence, we still stick to the term cathepsin, but now, when a new member of the family is discovered, we 
add numbers instead of letters[31]. An excellent reference and a classification of lysosomal proteases can be 
found in the MEROPS database (merops.sanger.ac.uk). 
Metalloproteinases, with the exception of lysosomal dipeptidase I, proteases with unknown mechanism of 
proteolytic cleavage, and the most recendy discovered threonine proteases are rarely found within lysosomes. 
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Mainly, lysosomal proteases are members of the aspartic, cysteine (Table 1, Chapter 2) , or serine proteinase 
families of proteolytic enzymes. 
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CHAPTER 2 
 
CYSTEINE CATHEPSINS: CATHEPSIN L 
      
 
There are 11 human cathepsins, which were originally identified as proteases that act in the lysosome. Recent 
work has uncovered non traditional roles for cathepsins in the extracellular space as well as in the cytosol and 
nucleus. There is strong evidence that subspecialized and compartmentalized cathepsins participate in many 
physiologic and pathophysiologic cellular processes, in particular multiple mechanisms increase cysteine 
cathepsin expression in tumors.  
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2.1 A brief description of Cathepsins 
The name cathepsin was initially proposed for those proteases which act in a slightly acidic 
environment[1,2].The cysteine cathepsins are predominantly endopeptidases, which are located intracellularly in 
endolysosomal vesicles. Later, the name cathepsin was introduced for the serine proteases cathepsins A and 
G, the aspartic proteases cathepsins D and E, and the lysosomal cysteine cathepsins. There are 11 human 
cysteine cathepsins, i.e., the cathepsins B, C, F, H, K, L, O, S, V, X and W, the sequences of which are 
known. The sequences were confirmed by bioinformatic analysis of the draft sequence of the human genome. 
The 11 human cysteine cathepsins (Table 1,2) belong to the papain subfamily of cysteine proteases[3]. 
 
 
Table 1. Human Cysteine Cathepsins[3] 
 
2.2   Localization and main properties 
The majority of cathepsins are ubiquitously expressed in human tissues: their expression profile indicates that 
these enzymes are involved in a normal cellular protein degradation and turnover. In contrast, cathepsins K, W 
and S show a restricted cell or tissue-specific distribution, indicating their more specific roles. For example, 
cathepsin K is highly expressed in osteoclasts, in most epithelial cells and in the synovial fibroblasts in 
rheumatoid arthritis joints[4] (Figure 1). Among the matrix-degrading enzymes, cathepsin K is the only enzyme 
for which an essential role in bone resorption has been unambiguously documented in mice and humans[5]. 
These two enzymes might be expected to have discrete functions and studies in mice deficient in cathepsin K 
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or cathepsin S have confirmed a role for cathepsin K in bone remodeling and Cathepsin S in MHC (major 
histocompatibility complex) class II antigen presentation.  
Cathepsin W (also lymphopain) is predominantly expressed in CD8+ lymphocytes and natural killer (NK) 
cells[6,7]. However, when cathepsin W expression has been downregulated using the shRNA approach, its 
essential role in the process of cytotoxity has been excluded[8]. 
 
 
Table 2.  General characteristics 
 
Cathepsin S is predominantly expressed in the professional antigen-presenting cells (APCs), such as the 
dendritic cells (DCs) and B-cells[9]. In addition, cathepsin V (also named L2) is highly homologous to cathepsin 
L, but in contrast to the ubiquitously expressed cathepsin L, its expression is restricted to thymus and 
testis[10,11]. Moreover, there is sufficient evidence that the specific physiological functions of the cathepsins 
might be at least partially attributed to their differences in localization inside and outside the cells[12,13,14]. This 
is consistent with the recent advances in the field of proteases that led to a new concept, based on proteases 
as important signaling molecules involved in the controlling mechanisms which play roles in many normal and 
pathological processes[15]. Cysteine cathepsins are commonly considered to be optimally active in a slightly 
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acidic pH and are mostly unstable at neutral pH When cathepsins are outside the lysosomes or extracellularly 
they can be inactivated irreversibly in a relatively rapid way at neutral pH[16]. 
 
                        
Figure 1. For example the cysteine cathepsins that are known to be expressed in tumour cells and tumour-associated cells, and have been 
identified as contributing to neoplastic progression. 
 
 
The extracellular localization of cysteine cathepsins often coincides with their increased expression and/or 
activity, indicating that pH is not the sole factor responsible for their activity. Twenty years ago, it was 
demonstrated that cathepsin B, from normal or tumor tissues, degraded purified extracellular-matrix 
components, type IV collagen, laminin and fibronectin, both under acid and neutral pH[17]. Cathepsins with 
strong elastolytic and collagenolytic activities are now known to be chiefly responsible for the remodeling of the 
extracellular matrix (ECM), thus contributing to various pathologies. The ECM consists of elastins, collagens 
and proteoglycans, which have all been identified as cathepsin's substrates[18]. Elastin was found to be 
cleaved by the cathepsins K, L, S, F, V and B, although they differ in their elastolytic activitiy. Cathepsin V was 
thus found to be the most potent enzyme, followed by the cathepsins K, S, F, L and B[19]. It was further 
demonstrated that the elastolytic activities of the cathepsins V and K could be inhibited by ubiquitously 
expressed glycosaminoglycans (GAGs), such as chondroitin sulfate, through the formation of cathepsin-GAG 
complexes. In contrast, cathepsin S, which does not form complexes with chondroitin sulfate, is not inhibited, 
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thus suggesting that there might exist some specific regulation of the elastolytic activities of cathepsins by 
GAGs[20]. Cysteine cathepsins such as cathepsin B and cathepsin L are expressed constitutively and are 
thought to participate in protein turnover. The expression of some cysteine cathepsins is regulated and is high 
in specific cell types. More surprisingly, studies in mice deficient in the constitutively expressed cathepsins L 
and B have established that these enzymes have specific functions in certain tissues. For example, cathepsin 
L-deficient mice exhibit phenotypes in skin and cardiac muscle[21,22] and cathepsin B-deficient mice exhibit 
reduced TNF (tumour necrosis factor)-induced apoptosis of hepatocytes[23]. Also unexpected is that there is 
redundancy of both constitutive and regulated cysteine cathepsins. In mice that are deficient in both 
cathepsins S and B[24], degradation of immune complexes is reduced by >80%, whereas in mice that are 
deficient in both cathepsins L and B[25], brain atrophy, which is induced by massive apoptosis of cerebral and 
cerebellar neurons, results in their death at 2–4 weeks. Cathepsins S and L are endopeptidases, but cathepsin 
B is both an exopeptidase and an endopeptidase, suggesting that, at least in immune-complex degradation 
and neuronal apoptosis, cathepsin B acts as an endopeptidase. Loss-of-function mutations of human 
cathepsins C and K are associated with Papillon–Lefevre syndrome and pycnodysostosis, respectively. 
Patients with Papillon–Lefevre syndrome have reduced activity and stability of neutrophil-derived serine 
proteases, but not of cytotoxic lymphocyte-derived serine proteases (granzymes)[26]. In cathepsin C-deficient 
mice, however, neither cytotoxic lymphocyte-derived serine proteases nor mast cell serine proteases 
(chymases) are activated[27]. This cysteine cathepsin therefore regulates a proteolytic pathway, in which there 
is the activation of other prostheses (figure 2). Cysteine cathepsins were long thought to function primarily 
intracellularly within endolysosomal compartments. However, there are exceptions; for example, cathepsin K, 
which is secreted into the resorptive pit between osteoclasts and bone, often termed an ‘extracellular’ 
lysosome. Studies on mice that are deficient in the cysteine cathepsins B, K and L have shown that all three of 
these cysteine cathepsins function both extracellularly and intracellularly to liberate thyroglobulin[28]. In 
cancers, as discussed in the next paragraph, there is evidence for the cysteine cathepsins functioning 
extracellularly as well as intracellularly. We emphasize studies on cathepsins B and L as these enzymes have 
been studied most thoroughly, however, even the functions of these two cysteine cathepsins in cancer are not 
well defined yet nor are their roles in tumor cells and the tumor-associated cells that contribute to neoplastic 
progression[3] (Figure  1). 
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Figure 2. Mechanisms of proteolytic regulation within the network. (a) Endogenous protein inhibitors can regulate proteolytic activity at many 
points in the network, allowing for tight regulation (or deregulation, if inhibitor expression is downregulated) of proteolytic activity. (b) Several 
proteases have been shown to degrade endogenous inhibitors, giving them the ability to increase the activity of other proteases indirectly. These 
interactions add further complexity to the network, and demonstrate how proteolytic signals can flow in multiple directions through different 
mechanisms. References for proteolytic interactions not described in the main text: cathepsin B can inactivate some serpins and TIMPs[29], 
serpinB13/hurpin and serpinB3/SCCA1 inhibit cathepsin L , cathepsin L inactivates serpinA1[30], and several MMPs can inactivate a variety of 
serpins. 
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2.3 Chatepsin L 
Cathepsin L, a lysosomal cysteine protease, plays an important role in the catabolism of proteins and 
consequently in the behavior of human cells[31]. Is produced as preprocathepsin L, transported via the Golgi 
apparatus as procathepsin L in secretory vesicles and then stored as mature cathepsin L in lysosomes[32]. 
 
2.3.1 Transcription and translation 
Genetic information[33,34]: 
Enzyme Nomenclature: Cathepsin L 
ECnumber: 3.4.22.15 
Other Aliases:  RP11-65B23.1, CATL, CTSL, FLJ31037, MEP  
Gene Name: CTSL1 
Chromosome: 9;   
Location:  9q21.33  
Annotation:  Chromosome 9, NC_000009.11 (90340974..90346384)   
Troen et al. first reporting[35] on the complex manner by which mouse cathepsin L transcription is regulated. 
Later on, regulation of cathepsin L gene transcription has been studied mainly in reproductive tissue. The 
cathepsin L and ADAMTS-1 genes are targets of the progesteron receptor signaling pathway during 
ovulation[36]. Cathepsin L mRNA is also upregulated during the implantation of the early trophoblast[37]. In male 
rats, FSH induced an increase in cathepsin L mRNA in late stages of the seminiferous tubular epithelium cycle 
in a cAMP-dependent manner[38]. Substantial work has been done to analyze the promoter regions of the 
human cathepsin L gene (CTSL) as well as to understand the regulation of different splice variants within the 
5′ untranslated region of the transcript. Indeed cathepsin L shows an ubiquitous organ distribution; more recent 
work has focused on the regulation of cathepsin L alternative translation. According to the presence of 
different  forms of cathepsin L in distinct subcellular and extracellular compartments, cathepsin L proteins can 
be initiated from downstream AUG sites[39], omitting the signal peptide that is normally present at the N 
terminus of lysosomal cathepsin L that routes the protein to the ER during its synthesis. The enormous 
increase of cathepsin L mRNA after Kirsten virus transformation of NIH-3T3 fibroblasts is a long-known 
phenomenon. Four splice variants of human cathepsin L mRNA have been reported, hCATL-A, -Al, -A2 and -
B, all differing in the 5’-UTR and thus coding for identical proteins  [40,41,42]. Later on three more isoforms were 
identified, all showing differences in amino acid sequences in the exon 1 moiety[43],. In any case they have all 
the encoding region between exon 2 and 7 (figure 3) 
Chapter 3 
 
Page 26 
 
                        
 
Figure 3. Structure of the various mRNAs at the 5’-UTR amplified by 5’-RACE PCR and confirmed by sequencing. The numbering for hCATLA 
mRNA (Gal et al., 1988) begins at the transcription site (+) of the hCATL. 
 
                  
 
Figure 4 . Partial cDNA Sequence of hCATL: Exon 1 and Transition to Exon 2. Numbering starts from the transcriptional start site (+1) of the 
hCAT-L gene. The exon/intron boundary (_), the translational start for hCAT-L (underlined) as well as the alternative splice sites (_) for both the 
hCATL-A2 and -A3 variants are indicated. 
 
 
For these isoforms the gene sequences appear to be quite different from each other only in the exon 1 
moieties where the sites in which the different alternative splicing starts are present (figure 4). Summarizing, 
we can say that a dominating isoform is evident, named hCATL-A3 in which the exon1 is 146 nucleotides 
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shorter than the one of hCATL-A. It seems to be the dominant form of cathepsin L transcripts in various cell 
lines, tissues and tumor samples examined in the relevant study. Subsequent DSD-Page experiments showed 
that the weight of the pre-propenzyme is 42 kDa. 
 
2.3.2 Biosynthesis, Processing and Trafficking 
Under normal conditions in healthy organisms, cells use various mechanisms to prevent potentially harmful 
and uncontrolled proteolytic activity. They include the compartmentalization of cathepsins within the lysosome 
or other organelles, zymogen activation, pH effects, regulation of proteolytic activities by small-molecule 
inhibitors and various endogenous protein inhibitors, or a combination of all these factors for an optimal 
enzyme function[44]. The organization of activation of protease from proenzyme and the role of mannose-6-
phosphate receptor is described in some detail in chapter 1. For cathepsins and, especially for cathepsin L, a 
similar activation occurs (Figure 5). As secreted proteins, cathepsins are synthesized with an N-terminal signal 
peptide that targets the protein to the lumen of the ER. The signal peptide is co-translationally cleaved and N-
linked glycosylation occurs within the ER. Similar to other proteases, cysteine cathepsins are synthesized as 
inactive proenzymes and require proteolytic processing for activity. The immature protein possesses an N-
terminal pro-region, which is removed to activate the enzyme, suggesting that the pro-region acts as an auto-
inhibitor. Indeed, synthetic peptides corresponding to pro-regions do function as specific inhibitors of the 
parent cathepsin in the case of cathepsin L and cathepsin-like cysteine proteases[45]. Further progress in 
understanding the nature of zymogen activation was obtained from the pro-cathepsin structures. The crystal 
structures of human pro-cathepsin L[46] showed that the pro-peptide chain folds (arranges itself) on the surface 
of the enzyme in an extended conformation and runs through the active-site cleft, in the opposite direction to 
the substrate, thereby blocking the access of the latter to the active site, which is already formed in the 
zymogen. In the structure of most pro-enzymes, hydrophobic interactions, salt bridges and hydrogen-bonding 
interaction within the pro peptide and between the pro-peptide and the mature enzyme do exist. Some early 
studies suggested that autocatalytic processing is a mono-molecular process, while others studies proposed 
inter- and intra-molecular mechanisms. This enigma has been recently clarified. It is now clear that the auto-
activation of cathepsins is a combination of a mono-molecular and a bi-molecular process[47]. Pro-cathepsin B 
possesses a low catalytic activity that is, nevertheless, sufficient to trigger the autocatalytic activation of the 
zymogen. This activity is the result of the pro-peptide dissociation from the active-site cleft as the first step in 
this process, which is in fact the only mono-molecular step in the process[48]. In the next step, which is already 
bi-molecular, this catalytically active zymogen molecule processes and activates another pro-cathepsin 
molecule in one or more steps. The mature cathepsin molecules generated in this way then initiate a chain 
reaction leading to a rapid activation of the remaining pro-cathepsin molecules. In addition to its role in auto-
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inhibition, the N-terminal pro-region of cathepsin L appears to be necessary for the correct folding of the 
protein[49], a finding that is also true for papain. 
 
 
 
Figure 5. Cathepsin structures and traditional and nontraditional protease trafficking. Cathepsins contain a signal peptide (blue) that directs 
insertion of the nascent polypeptide chain into the ER. Within the ER, the signal peptide is cleaved and the protein folds with the assistance of the 
proregion (red). Disulfide bond formation (indicated by S-S) and N-linked glycosylation with high-mannose glycans subsequently occurs in the ER. 
Within the Golgi, mannose residues are phosphorylated to form m6p, which is used to route the protein into the endosomal/lysosomal compartment 
via the m6p receptor. Upon initial acidification of the endosome, cathepsins are activated, which leads to cleavage of the proregion and further 
activation of the cathepsin, resulting in further proteolytic processing in the lysosome into heavy and light chains (yellow). A portion of the 
cathepsins is not converted to the m6p form and as a result is shunted into the exocytosis pathway. Conversion to m6p appears to be rate limiting, 
as overexpression of a given cathepsin greatly increases the proportion of the enzyme in this pathway. Ribbon diagrams depict the structure of 
mature cathepsin L in the extracellular matrix and in the lysosome. The ribbon colors correspond to the colors used in the diagram on the left. 
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Mutations destabilizing the interface between the helices prevent correct folding of the protein[50]. Folding of 
the pro-region may precede folding of the full protein, thereby providing a scaffold which then directs the 
folding of the remaining domains. The full structure would be stabilized by the formation of disulfide bonds that 
prevent unfolding once the pro-region has been removed (Figure 4). Initial glycosylation generates high 
mannose glycans within the ER. Cathepsins destined for the lysosome are further processed in the Golgi 
apparatus by modification of mannose residues to mannose-6-phosphate (m6p). Two to three lysine residues 
separated by 34 Å appear to be critical in the recognition motif[51]. Upon acidification in endosomes, cathepsins 
become active and begin proteolytic processing, with cleavage within the pro-region, allowing pro-region 
dissociation from the enzyme as mentioned above. This results in an active, single chain form of the protein. 
Upon arrival at the lysosome, further processing cleaves the protein into two chains. Active cathepsins may 
also be recruited from late endosomes or lysosomes for secretion into the extracellular space via Ca2+-
mediated fusion of these organelles with the plasma membrane. In addition, a minor population of cathepsins 
(approximately 5%) does not travel to the lysosome but is instead secreted as a pro-enzyme. Furthermore, 
alternative splicing and exon skipping can lead to cathepsin forms that lack the signal peptide, and these can 
subsequently localize to the nucleus and mitochondrial matrix[52]. Recent data suggest that truncated forms of 
cathepsin L are important in regulating the cytoskeleton of kidney podocytes[53], whereas others data suggest 
that mature cathepsin L is present outside lysosomes, e.g., during histone processing in embryonic stem 
cells[54]. These cathepsin L variants have been previously shown to arise by translation from an alternate 
downstream AUG site[39] and to be located in the nucleus of fibroblasts, in which they can cleave the 
transcription factor cut-like home[39]. Cathepsin L also processes histone H3 during mouse embryonic stem cell 
differentiation (25). Although conventional cathepsin L cleaves various proteins very efficiently, due to the 
denaturing conditions and low pH of the lysosome, cytosolic and nuclear cathepsin L exhibit remarkable 
substrate specificity that allows a very specific enzymatic activity at cytosolic or nuclear pH[55] .  
 
 
2.3.3 Structure and Specificity 
Understanding the interactions between cysteine cathepsins and their substrates has been and remains the 
main challenge in the research on cysteine cathepsins. Papain served as the model in the pioneering work of 
Schechter and Berger[56], in which they proposed the nomenclature for the positions of the substrate residues 
(P) and the sub-sites (S) where they bind to the surface of a protease. The positions and sub-sites were 
numbered in both directions from the scissile bond between the residues P1 and P1′ onwards, where the non-
primed side refers to the N-terminal part and the primed side to the C-terminal part of the substrate. In their 
pioneering work, they found that adding residues longer  than 7 alanins to peptides does not affect the kinetics 
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of their degradation and concluded that there are seven substrate residues binding into seven sub-sites from 
S4 to S3′. Three decades later, the definition of the substrate binding sites was revised based on an insight 
provided by the crystal structures of the complexes with small-molecule, substrate-mimicking inhibitors[57]. 
These structures show that a substrate binds along the active-site cleft in an extended conformation Figure 6. 
 
                                           
 
Figure 6. 3D schematic representation of the substrate-binding sites of papain-like proteases along the active-site cleft. The representation is 
based on the proposed revised definition of substrate-binding sites based on the crystal structures of substratemimicking inhibitors bound to the 
protease's active sites [57]. The substrate-binding sites of the papain-like proteases are located on the left (S1, S3, S2′) and right (S2, S1′) side of the 
active-site cleft in accordance with the standard view orientation. According to papain numbering, L-domain loops include residues Gln19-Cys25 
and Arg59-Tyr67 whereas R-domain loops contain residues Leu134-His159 and Asn175- Ser205, respectively. The active-site residues Cys25 and 
His159 and the disulphide Cys22-Cys63 are indicated.  
 
A 3D-based sequence alignment of the mature form of the nine cysteine cathepsins with a known 3D structure 
exhibits conservation of the active-site residues (Cys25 and His163, for cathepsin L); these residues interact 
with the main chain of the bound substrate, (Gln19, Gly68, Trp183), the N-terminus Pro2 and certain Cys 
residues do interact as well. Figure 7 shows the papain-like fold of cathepsin L. It is composed of two domains, 
referred to as the left (L-) and right (R-) ones, in accordance with the standard view. The L-domain contains 
three α-helices. The longest, i.e., the vertical helix, known also as the central helix, is over 30 residues long. 
The R-domain is a kind of β-barrel with the front strand(s) forming a coiled structure. At the bottom, the barrel 
is enclosed by an α-helix. The reactive site histidine is located at the top of the sheet forming the barrel. The 
two-domain interface opens at the top, forming the active-site cleft. In its center are the reactive site residues, 
Cys25 and His163, each coming from a different domain. The reactive site cysteine is located at the N-
terminus of the central helix of the L-domain, whereas the histidine is located within the β-barrel residues of 
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the R-domain. These two catalytic residues form the thiolate-imidazolium ion pair, which is essential for the 
proteolytic activity of the enzymes[20]. 
                 
                                                  
 
Figure 7. Fold of the mature form of cysteine cathepsins–endopeptidases. The fold of the two-chain form of native cathepsin L (1icf) is shown in 
the green ribbon representation. The parts corresponding to the secondary structure elements,α-helices and β-sheets, are shown in blue and red 
color, respectively. The side chains of the reactive-site cysteine (Cys25) and histidine (His163) are indicated in a ball-and-stick representation. 
 
The active-site surface is composed of the residues coming from four loops located on both domains (Figure 
6). The two L-domain loops are short and cross-connected with a disulfide bond. The two R-domain loops are 
much larger and form the lid of the β-barrel hydrophobic core. The substrate binds along the active-site cleft in 
an extended conformation[57]. Its side chains make alternating contacts with the L- and R-domains. The two 
loops on the L-domain and their bridged interface provide the surface for the side chains of the P3, P1 and P2′ 
residues, whereas the loops and residues of the R-domain provide the binding surface for the P2 and P1′ 
residues. An exception to this is the P2 residue. According to the proposed model[58], the P2 residue interacts 
with both domains. 
 
2.3.4 Cathepsin L and Cancer 
Several members of the cysteine cathepsin family have been implicated in cancer progression on the basis of 
their increased expression, activity and mislocalization in various human and mouse tumors (Figure 8)[59,60]. 
Furthermore, in some of these cancers, the changes in cysteine cathepsin expression or activity have 
diagnostic or prognostic value[61]. In terms of which cysteine cathepsins are specifically involved in cancer, 
cysteine cathepsins B and L have been investigated most intensively, and invariably their increased 
expression and/or activity correlates with malignant progression. It is now clear that the cathepsins have an 
important role in both tumor progression and invasion, which is supported by the numerous clinical reports and 
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results from experimental mouse-cancer models[62]. Elevated cathepsin expression and/or activity has been 
shown to be associated with cancer progression in a number of different types of tumors. Moreover, the level 
of cathepsin expression positively correlated with a poor prognosis for cancer patients and was suggested to 
be a potential prognostic marker[63]. In addition, serum cathepsin levels have been positively correlated with 
metastasis[64]. The roles of cathepsins in the individual tumor-biological processes were also confirmed ex vivo 
using cell-based systems. As such, the cathepsins B, L and some others have been shown to promote the 
migration and invasion of tumor cells[65]. Several mechanisms are being proposed for this role of cathepsins 
(Figure 8).  
 
                   
 
Figure 8. Role of cathepsin L in tumorigenesis: effects on proliferation and apoptosis, angiogenesis, invasion and metastasis. 
 
When present in the acidic lysosomal compartment, cathepsin L is proteolytically active. Therefore, 
acidification of the local environment of a tumor caused by increased anaerobic glycolysis in cancer cells 
facilitates the activity of extracellular cathepsin L[66,67]. In an acidic environment, cathepsin L is able to degrade 
components of the ECM such as collagen types I and IV, fibronectin and laminin. Cathepsin L has been 
proved to be upregulated in a variety of malignancies: breast, lung, gastric, colon, head and neck carcinomas, 
melanomas, and gliomas[68,69]. In addition, the level of cathepsin L expression correlates positively with the 
degree of malignancy. As mentioned before, expression of cathepsin L is exclusively elevated in cancer cells 
and it may therefore be an optimal therapeutic target than other cathepsins[70].  A possible mechanism by 
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which cathepsin L induces apoptosis is by cleaving Bid, a Bcl2 family member[71]. The cleavage of Bid results 
in cytochrome C release from the mitochondria, which induces apoptosis. Di Piazza et al. studied cultures of 
human glioma cells transfected with parvovirus H-1, and found increased cell death[72]. They found that 
increased glioma cell death was associated with accumulation of cathepsin B and L in the cytosol and reduced 
levels of cystatin B and C, two cathepsin inhibitors. These findings suggest that cathepsin L has a pro-
apoptotic function, yet they do not prove a causal relationship. By contrast, Gocheva et al. suggest that 
reduced cathepsin L expression increases apoptosis[68]. They used RIP1-Tag2 transgenic mice that develop 
multiple pancreatic islet tumors at 12 to 14 weeks of age. Cathepsin L knockout mice showed decreased cell 
proliferation and tumour growth[73]. Tumors from cathepsin L knockout mice showed increased apoptosis 
compared to controls, without evident defects in tumour vascularity. This suggests an effect on apoptosis, 
independent of angiogenesis (see also the Angiogenesis section). A possible explanation for this effect on 
apoptosis was recently suggested by Navab et al. Reduced cathepsin L expression was found to diminish IGF-
1 receptor responsiveness, thus leading to increased apoptosis in vivo[74].  
 
2.3.4.1  Inhibitors 
The discovery of an epoxysuccinyl-based inhibitor E-64 [L-trans-Epoxysuccinyl-leucylamido(4-
guanidino)butane], was very important for the research on cysteine cathepsins[75]. It selectively alkylates the 
reactive site cysteine and remains covalently bound to the enzyme. Because it reacts almost exclusively with 
the reactive site cysteine of papain-like proteases, it has immediately become a widely used indicator of the 
proteolytic activity of cysteine cathepsins. Together with its derivatives that have improved cell-permeability 
properties, it was of great importance for progress in understanding the function and properties of cysteine 
cathepsins, ranging from a titration of their activity to an assessment of their activity in cell lysates, cultures 
and living organisms. E-64 is a non-selective inhibitor of all the cysteine cathepsins, with the exception of 
cathepsin C, which is only weakly inhibited. In addition, E-64 also efficiently inhibits calpain[76]. The effect of 
the broad-spectrum inhibitor E-64 has been studied by Rofstad et al.[77]. They used three different human 
melanoma cell lines in which proteolytic enzymes, among which cathepsin L was included, were upregulated 
due to an acidic environment. They demonstrated that treatment with E-64 decreased cell invasiveness in vitro 
and metastasis in vivo. Another broad-spectrum irreversible cathepsin inhibitor, JPM-OEt, was studied in 
cancer as well[78]. As described in the paragraph titled “Angiogenesis”, an RIP1-Tag2 transgenic mice model 
was used for these studies. In an intervention trial, mice were administrated with JPM-OEt to halt the growth of 
nascent solid tumours. A significant shift was observed towards more benign, encapsulated tumours. When 
using JPM-OEt in mice that had already developed tumours, the incidence of both invasive and micro-invasive 
carcinomas was significantly reduced. Both trials lead the researchers to the conclusion that cathepsin activity 
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contributes to the invasiveness of carcinomas[78]. However, no distinction can be made between effects of the 
inhibitor on cathepsin L and other cathepsins. In addition to broad-spectrum cathepsin inhibitors, several 
inhibitors that are specific for cathepsin L are available. One of the most promising inhibitors is CLIK-148 
(Table 3), which was developed by Katunuma et al[79] . Intravenous or oral administration of CLIK-148 in mice 
was shown to reduce bone resorption caused by human mandibular squamous cell carcinoma and calvaria 
metastases of colon carcinoma. Z-FF-FMK is an irreversible and selective inhibitor of cathepsin L, which at 
higher concentrations also inhibits cathepsin B (Table 3). Nagaraj and Zacharias found a decrease in 
invasiveness in two human oral squamous cell carcinoma (OSCC) cell lines after treatment with z-FF-FMK[80]. 
 
2.4 References 
[1] C.E. Chwieralski, T. Welte, F. Buhling, Cathepsin-regulated apoptosis Apoptosis 11 (2006) 143-149 
[2] A.J. Barrett, N.D. Rawlings, J.F. Woessner (Eds.), Handbook of Proteolytic Enzymes 2nd Ed, Elsevier, Amsterdam, 2004. 
[3] M.M. Mostafa, B.F. Sloane, Cysteine cathepsin: multifunctional enzyme in cancer, Nat Rev Cancer 6 (2006) 764-775  
[4] H.J. Salminen-Mankonen, J. Morko, E. Vuorio, Role of cathepsin K in normal joints and in the development of arthritis, Curr. Drug 
Targets 8 (2007) 315–323. 
[5] M. Asagiri, H. Takayanagi, The molecular understanding of osteoclast differentiation, Bone 40 (2007) 251–264. 
[6] C. Linnevers, S.P. Smeekens, D. Brömme, Human cathepsin W, a putative cysteine protease predominantly expressed in CD8+ T-
lymphocytes, FEBS Lett. 405 (1997) 253–259. 
[7] T. Wex, H. Wex, R. Hartig, S. Wilhelmsen, P. Malfertheiner, Functional involvement of cathepsin W in the cytotoxic activity of NK-92 
cells, FEBS Lett. 552 (2003) 115–119. 
[8] C. Stoeckle, C. Gouttefangeas, M. Hammer, E. Weber, A. Melms, E. Tolosa, CathepsinWexpressed exclusively in CD8+ T cells and NK 
cells, is secreted during target cell killing but is not essential   for cytotoxicity in human CTLs, Exp. Hematol. 37 (2009) 266–275. 
[9] L.C. Hsing, A.Y. Rudensky, The lysosomal cysteine proteases in MHC class II antigen presentation, Immunol. Rev. 207 (2005) 229–241. 
[10] I. Santamaria, G. Velasco, M. Cazorla, A. Fueyo, E. Campo, C. Lopez-Otin, Cathepsin L2, a novel human cysteine proteinase produced 
by breast and colorectal carcinomas, Cancer Res. 58 (1998) 1624–1630. 
[11] D. Bromme, Z. Li, M. Barnes, E. Mehler, Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, 
enzymatic characterization, and chromosomal localization, Biochemistry 38 (1999) 2377–2385. 
[12] A.J. Barrett, N.D. Rawlings, J.F. Woessner (Eds.), Handbook of Proteolytic Enzymes, 2nd Ed, Elsevier, Amsterdam, 2004. 
[13] T. Zavašnik-Bergant, B. Turk, Cysteine cathepsins in the immune response, Tissue Antigens 67 (2006) 349–355. 
[14] K. Brix, A. Dunkhorst, K. Mayer, S. Jordans, Cysteine cathepsins: cellular roadmap to different functions, Biochimie 90 (2008) 194–207. 
[15] B. Turk, Targeting proteases: successes, failures and future prospects, Nat. Rev. Drug Discov. 5 (2006) 785–799. 
[16] B. Turk, J.G. Bieth, I. Bjork, I. Dolenc, D. Turk, N. Cimerman, J. Kos, A. Colic, V. Stoka, V. Turk, Regulation of the activity of lysosomal 
cysteine proteinases by pH-induced inactivation and/or endogenous protein inhibitors, cystatins, Biol. Chem. Hoppe Seyler 376 (1995) 
225–230. 
[17] M.R. Buck, D.G. Karustis, N.A. Day, K.V. Honn, B.F. Sloane, Degradation of extracellular-matrix proteins by human cathepsin B from 
normal and tumour tissues, Biochem. J. 282 (1992) 273–278. 
[18] S.P. Lutgens, K.B. Cleutjens, M.J. Daemen, S. Heeneman, Cathepsin cysteine proteases in cardiovascular disease, FASEB J. 21 (2007) 
3029–3041. 
[19] D. Bromme, K. Okamoto, B.B. Wang, S. Biroc, Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in 
osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme, J. Biol. Chem. 
271 (1996) 2126–2132. 
Cysteine Protease: Cathepsin L 
 
                                                                                                                                                                                   Page 35 
 
[20] V. Turk; V. Stoka; O. Vasiljeva; R. Miha; T. Sun; B. Turk; D. Turk; Cysteine cathepsin: From structure, function and regulationto new 
frontiers, Biochemica et Biophysica Acta 1824 (2012) 68-88 
[21] Roth, W. et al. Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle 
cycling. FASEB J. 14, (2000).2075–2086  
[22] Stypmann, J. et al. Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc. Natl Acad. Sci. USA 
99, (2002)6234–6239. 
[23] Reinheckel, T., Deussing, J., Roth, W. & Peters, C. Towards specific functions of lysosomal cysteine peptidases: phenotypes of mice 
deficient for cathepsin B or cathepsin L. Biol. Chem. 382, 735–741 (2001). 
[24] Driessen, C., Lennon-Dumenil, A. M. & Ploegh, H. L. Individual cathepsins degrade immune complexes internalized by antigen-
presenting cells via Fcγ receptors. Eur. J. Immunol. 31, 1592–1601 (2001). 
[25] Felbor, U. et al. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc. Natl Acad. Sci. USA 99, (2002)7883–7888. 
[26] Pham, C. T., Ivanovich, J. L., Raptis, S. Z., Zehnbauer, B. & Ley, T. J. Papillon–Lefevre syndrome: correlating the molecular, cellular, 
and clinical consequences of cathepsin C/dipeptidyl peptidase I deficiency in humans. J. Immunol. 173, (2004)7277–7281. 
[27] Caughey, G. H. New developments in the genetics and activation of mast cell proteases. Mol. Immunol. 38, (2002)1353–1357. 
[28] Friedrichs, B. et al. Thyroid functions of mouse cathepsins B, K, and L. J. Clin. Invest. 111, (2003)1733–1745. 
[29] G.  Kostoulas, Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases FEBS 
Lett. 455 (1999) 286-290 
[30] D.A. Johnson, Cathepsin L inactivates alpha1-proteinase inhibitor by cleavage in the reative site region J. Biol. Chem. 261 (1986) 14748-
14751. 
[31] D. Jean, N. Rousselet, R. frade, Cathepsin L expression in up-regulated by hypoxia in human melanoma cells: role of its 5’-untraslated 
region, Biochem J. 413 (2008) 125-134 
[32] I. Kazumi, K. Eiki, N. Katunuma, Gene structure and 5'-upstream sequence of rat cathepsin L, FEBS Lett. 259 (1989) 71-74  
[33] http://www.uniprot.org/uniprot/P07711 
[34] http://www.brenda-enzymes.info/ 
[35] B. R. Troen, S. S. Chauhan, D. Ray, M. M. Gottesman Downstream sequences mediate induction of mouse cathepsin L promoter by 
phorbol esters. Cell Growth Diff. 2, (1991) 23 – 31. 
[36] R. L. Robker, D. L. Russell, L. L. Espey, J. P. Lydon, B. W. O’Malley, J. S.  Richards, Progesterone regulated genes in the ovulation 
process: ADAMTS 1 and cathepsin L proteases. Proc. Natl. Acad. Sci. USA 97, (2000) 4689 – 4694. 
[37] S. Afonso, L. Romagnano,  B. Babiarz, Expression of cathepsin proteinases by mouse trophoblast in vivo and in vitro. Dev. Dyn. 216, 
(1999) 374 – 384. 
[38] T. L. Penttila, H. Hakovirta, P. Mali, W. W.  Wright, M. Parvinen, Follicle stimulating hormone regulates the expression of cyclic protein 
2/cathepsin L messenger ribonucleic acid in rat Sertoli cells in a stage specific manner. Mol. Cell. Endocrinol. 113, (1995) 175 – 181. 
[39] Goulet B, et al. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux 
transcription factor. Mol Cell. 2004;14(2):207–219. 
[40] S. Gal, C. M. Willingham, M. M. Gottesman, Processing and Lysosomal Localization of a Glycoprotein Whose Secretion Is 
Transformation Stimulated The J. Cell Biology 100 (1985) 535-544 
[41] L. J. Joseph, L. C. Chang, C. Stamenkovich, V. P. Sukhatme, Complete nucleotide and deduced amino acid sequences of human and 
murine preprocathepsin L. An abundant transcript induced by transformation of fibroblasts. J. Clin. Invest. 81, (1988) 1621 – 1629. 
[42] D. K. Rescheleit, W. J. Rommerskirch,B.  Wiederanders Sequence analysis and distribution of two new human cathepsin L splice 
variants. FEBS Lett. 394, (1996)  345 – 348. 
[43] A. Abudula, W. Rommerskirch, E. Weber, D. Gunther, B. Wiederanders, Splice Variants of Human Cathepsin L mRNA Show Different 
Expression Rates Bio. Chem. 382 (2001) 1583-1591 
[44] S.S. Twining, Regulation of proteolytic activity in tissues, Crit. Rev. Biochem. Mol. Biol. 29 (1994) 315–383. 
Chapter 3 
 
Page 36 
 
[45] J. Reiser, B. Adair, T. Reinheckel, Specialized roles for cysteine cathepsins in health and disease The J. Clin. Inves. 120 (2010)  3421-
3431. 
[46] R. Coulombe, P. Grochulski, J. Sivaraman, R. Menard, J.S. Mort, M. Cygler, Structure of human procathepsin L reveals the molecular 
basis of inhibition by the prosegment, EMBO J. 15 (1996) 5492–5503. 
[47] J. Rozman, J. Stojan, R. Kuhelj, V. Turk, B. Turk, Autocatalytic processing of recombinant human procathepsin B is a bimolecular 
process, FEBS Lett. 459 (1999) 358–362. 
[48] J.R. Pungercar, D. Caglic, M. Sajid, M. Dolinar, O. Vasiljeva, U. Pozgan, D. Turk, M. Bogyo, V. Turk, B. Turk, Autocatalytic processing of 
procathepsin B is triggered by proenzyme activity, FEBS J. 276 (2009) 660–668. 
[49] Tao K, Stearns NA, Dong J, Wu QL, Sahagian GG. The proregion of cathepsin L is required for proper folding, stability, and ER exit. 
Arch Biochem Biophys. 1994;311(1):19–27. 
[50] Schilling K, Pietschmann S, Fehn M, Wenz I, Wiederanders B. Folding incompetence of cathepsin L-like cysteine proteases may be 
compensated by the highly conserved, domain-building N-terminal extension of the proregion. Biol Chem. 2001; 382(5):859–865. 
[51] Braulke T, Bonifacino JS. Sorting of lysosomal proteins. Biochim Biophys Acta. 2009;1793(4):605–614. 
[52] Muntener K, Zwicky R, Csucs G, Rohrer J, Baici A. Exon skipping of cathepsin B: mitochondrial targeting of a lysosomal peptidase 
provokes cell death. J Biol Chem. 2004;279(39):41012–41017. 
[53] Faul C, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 
2008;14(9):931–938. 
[54] Duncan EM, et al. Cathepsin L proteolytically processes histone H3 during mouse embryonic stem cell differentiation. Cell. 
2008;135(2):284–294. 
[55] Lohmuller T, et al. Toward computer-based cleavage site prediction of cysteine endopeptidases. Biol Chem. 2003;384(6):899–909. 
[56] I. Schechter, A. Berger, On the size of the active site in proteases. I. Papain, Biochem. Biophys. Res. Commun. 27 (1967) 157–162. 
[57] D. Turk, G. Guncar, M. Podobnik, B. Turk, Revised definition of substrate binding sites of papain-like cysteine proteases, Biol. Chem. 
379 (1998) 137–147. 
[58] D. Turk, B. Turk, V. Turk, Papain-like lysosomal cysteine proteases and their inhibitors: drug discovery targets? Biochem. Soc. Symp. 70 
(2003) 15–30. 
[59] Berdowska, I. (2004) Cysteine proteases as disease markers. Clin. Chim. Acta 342, 41–69 
[60] Joyce, J.A. et al. (2004) Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage 
tumorigenesis. Cancer Cell 5, 443-453 
[61] Jedeszko, C. and Sloane, B.F. (2004) Cysteine cathepsins in human cancer. Biol. Chem. 385, 1017–1027 
[62] V. Turk, J. Kos, B. Turk, Cysteine cathepsins (proteases) — on the main stage of cancer? Cancer Cell 5 (2004) 409–410. 
[63] T.T. Lah, M. Cercek, A. Blejec, J. Kos, E. Gorodetsky, R. Somers, I. Daskal, Cathepsin B, a prognostic indicator in lymph node-negative 
breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators, Clin. Cancer Res. 6 (2000) 578–584. 
[64] T. Hirano, T. Manabe, S. Takeuchi, Serum cathepsin B levels and urinary excretion of cathepsin B in the cancer patients with remote 
metastasis, Cancer Lett. 70 (1993) 41–44. 
[65] Z. Yang, J.L. Cox, Cathepsin L increases invasion and migration of B16 melanoma, Cancer Cell Int 7 (2007) 8. 
[66] Hashimoto Y, Kondo C, Kojima T, Nagata H, Moriyama A, Hayakawa T, Katunuma N. Significance of 32-kDa cathepsin L secreted from 
cancer cells. Cancer Biotherapy & Radiopharmaceuticals 21 (3), 217–224, 2006. 
[67] Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells 
in athymic nude mice. Cancer Research 66 (13), 6699–6707, 2006. 
[68] Gocheva V, Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6 (1), 60–64, 2007. 
[69] Kos J, Stabuc B, Schweiger A, Krasovec M, Cimerman N, Kopitar-Jerala N, Vrhovec I. Cathepsins B, H, and L and their inhibitors stefin 
A and cystatin C in sera of melanoma patients. Clinical Cancer Research 3 (10), 1815–1822, 1997. 
Cysteine Protease: Cathepsin L 
 
                                                                                                                                                                                   Page 37 
 
[70] Hazen LG, Bleeker FE, Lauritzen B, Bahns S, Song J, Jonker A, Van Driel BE, Lyon H, Hansen U, Köhler A, Van Noorden CJ. 
Comparative localization of cathepsin B protein and activity in colorectal cancer. Journal of Histochemistry and Cytochemistry 48 (10), 
1421–1430, 2000. 
[71] Stoka V, Turk B, Schendel SL, Kim TH, Cirman T, Snipas SJ, Ellerby LM, Bredesen D, Freeze H, Abrahamson M, Brömme D, Krajewski 
S, Reed JC, Yin XM, Turk V, Salvesen GS. Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most 
likely route. Journal of Biological Chemistry 276 (5), 3149–3157, 2001. 
[72] Di Piazza M, Mader C, Geletneky K, Herrero Y, Calle M, Weber E, Schlehofer J, Deleu L, Rommelaere J. Cytosolic activation of 
cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. Journal of Virology 81 (8), 4186–4198, 
2007. 
[73] Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D, Joyce JA. Distinct roles for cysteine cathepsin genes in 
multistage tumorigenesis. Genes & Development 20 (5), 543–556, 2006. 
[74] Navab R, Pedraza C, Fallavollita L, Wang N, Chevet E, Auguste P, Jenna S, You Z, Bikfalvi A, Hu J, O'Connor R, Erickson A, Mort JS, 
Brodt P. Loss of responsiveness to IGF-I in cells with reduced cathepsin L expression levels. Oncogene 27 (37), 4973–4985, 2008. 
[75] K. Hanada, M. Tamai, M. Yamagishi, S. Ohmura, J. Sawada, I. Tanaka, Isolation and characterization of E-64, a new thiol protease 
inhibitor, Agric. Biol. Chem. 42 (1978) 523–528. 
[76] C. Parkes, A.A. Kembhavi, A.J. Barrett, Calpain inhibition by peptide epoxides, Biochem. J. 230 (1985) 509–516. 
[77] Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells 
in athymic nude mice. Cancer Research 66 (13), 6699–6707, 2006 
[78] Joyce JA, Hanahan D. Multiple roles for cysteine cathepsins in cancer. Cell Cycle 3 (12), 1516–1619, 2004. 
[79] Katunuma N, Tsuge H, Nukatsuka M, Fukushima M. Structure-based development of cathepsinL inhibitors and therapeutic applications 
for prevention of cancer metastasis and cancer-induced osteoporosis. Advances in Enzyme Regulation 42, 159–172, 2002. 
[80] Nagaraj NS, Zacharias W. Cigarette smoke condensate increases cathepsin-mediated invasiveness of oral carcinoma cells. Toxicology 
Letters 170 (2), 134–145, 2007. 
 
 
 
Page 38 
 
 
CHAPTER 3 
 
CHELIDONIUM MAJUS 
 
 
               
 
In this chapter a brief description of several components of Chelidonium majius (C. majus) is afforded. C. 
majus is a herb widely used in the folk medicine of several different countries and it is being studied now for its 
potential anticancer properties in different laboratories. Several C. majus components were analyzed in our 
laboratory with regard to many different actions included inhibition of Cathepsin L.  
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1.1 A brief description of Chelidonium Majus 
The name (Celandine) (Figure 1), in ancient times called "grass of the Swallows", derives from the greek word 
"" which  means "swallow". The name is thought to refer to the fact that this herb grows at swallows’ 
arrival and withers at their departure, or also depending on the fact that these birds rub a branch of this 
grass over their offspring’s blind eyes, restoring their vision. 
 
                                   
 
Figure 1. Detail of Chelidonium majus. 
 
1.1.1 Systematic Framework 
 
Reign: Plantae 
 
Division: Magnoliophita 
 
Class: Magnoliopside (Dycotiledones) 
 
Order: Papaverales 
 
Family: Papaveraceae 
 
Type: Chelidonium 
 
Species: Chelidonium majus 
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1.1.2 Botanical Description 
The C. majus is a perennial herb about 40-80 cm high, which grows wild in areas uncultivated, over rocks and 
walls. The plant has a thin stem, slightly hairy, very branched and swollen nodes. The leaves are alternate, 
lobed, imparipinnate, finely hairy or hairless, bluish-green color from the upper surface and a more light or 
grayish underneath. The flowers are constituted by two sepals lapsed visible only in the bud, and a corolla of 
four petals arranged in a cross with yellow numerous stamens and ovary central excess. The fruit is a siliqua 
containing a green row of small yellowish-white seeds. The most distinctive of the plant is presence of the 
latex orange leaking if the branches are broken and which, in contact with the air, oxidizes rapidly taking on a 
brownish-blackish. The roots, brown-orange, have a taproot and is easily distinguished root primary by 
numerous secondary roots (Figure 2) [1,2].. 
 
1.2.3 Geographical Distribution 
 
The C. maius is native to Europe but has naturalized in Asia, Northern and North Africa. In Italy the Chelidonia 
has spread from the Mediterranean regions to mountain areas where it grows wild in shady places, between 
the hedges, in the woods and ruderal areas[3].. 
                                    
 
Figure 2. Components of the plant Chelidonium majus. 
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1.2 General chemical and pharmacological properties of Chelidonium majus 
1.2.1 Folk Medicine 
C. majus has long been known for some of its medicinal properties and is used in folk medicine in many 
countries. The latex is used as a remedy for dermatitis, herpes, and warts. The plant is also recognized to 
possess mitogenic, antifungal and antispasmodic propertie. Two of the many recipes found in the literature are 
reported below: 
 
 INTERNAL USE. Make an infusion using one teaspoon of dried leaves Celandine in a liter of water 
previously boiled, leave to infuse for 10 minutes and take over three cups a day between meals.  
 
 EXTERNAL USE. In the case of warts, corns, calluses and scaly dermatitis, apply fresh latex 3-4 times 
a day doing[4]. 
 
Despite its spread in folk medicine, there are numerous cases of acute hepatitis arising from the use of acute 
Celandine Chelidonia reported to health authorities in various countries, also in relation to the intake of simple 
infusions and decoctions. The risk / benefit ratio is unfavorable, and so far the plant should not be used in 
phytotherapy[5].  
 
1.2.2 Major constituents of Chelidonium majus, and their pharmacological activities 
Literature data report a big variety of compounds contained in C. majus belonging to several different chemical 
classes. Among the most important seem alkaloids, which are thought to account for many therapeutic effects, 
are comprised. Motreover small organic acids, lactones, carotenoids, vitamins, flavonoids, phytosterols, 
saponins and proteins are contained in C. majus[6,7]. Alkaloids are organic compounds containing the nitrogen 
atom, which even characterized by heterogeneous chemical functionalities, share some common 
characteristics: 
 
   Most of them give alkaline reaction (but not all alkaloids are bases); 
 
   They have mostly vegetable origin, with only a few exceptions; 
  
 Their nitrogen atom in mostly included in the heterocyclic ring. However, in some alkaloids the 
nitrogen is located out of the cycles 
 
 They induce, even at low concentrations, important biological actions 
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The isochinoline alkaloids are characterized by the presence in the molecule of an isochinoline  nucleus, in 
some cases a reduced or open cycle. A brief description of the alkaloids contained in C. majus which are 
mentioned in this thesis is reported below. 
 
Canadine 
 
Studies on the pharmacological action of canadine indicate that this alkaloid is a potent inhibitor of 
acetylcholinesterase[9]. 
 
Chelerythrine 
 
Several studies reported in the literature show that chelerythrine has a powerful cytotoxic action. It inhibits the 
protein kinase C [10] and completely suppresses the cell migration[11].It is an irritating agent to the human skin. 
1.2 chelerythrine also inhibits the growth of bacteria (Staphylococcus aureus, Aeromonas hydrophila and 
Escherichia coli)[12].. 
 
Registration number: 522-97-4 
PabChem ID: 34458 
Molecular weight:339.38504 
[g/mol] 
Registration number: 34316-15-9 
PubChem ID: 2703 
Molecular weight: 348.37192 [g/mol] 
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 Berberine 
 
Many different biological actions are reported in the literature on regard to berberine. Among them, the ones 
listed below are worth of mention: the induction of smooth muscle relaxation of blood vessels[13]; the anti-
depressive action carried out through the regulation of neurotransmitters (dopamine, norepinephrine and 
serotonin)[14], a potent antiangiogenic action, which could have interesting implications for the treatment of 
cancer[15]. Induction of apoptosis in melanoma cells[16] is also reported.. Berberine is also thought to be useful 
as adjuvant therapy in the treatment of hyper-expression of HER2 protein in cells breast cancer[17]. Berberine 
may have positive effects in treatment of patients with obesity due to type 2 diabetes because it reduces the 
accumulation of lipids and inhibits the differentiation of adipocytes[18]. In diabetic rats significantly berberine 
decreased the levels of triglycerides and fasting glucose[19]. Berberine also shows a potential anti-inflammatory 
action, shifting the Th1/Th2 polarization balance towards Th2[15]., and Finally the Berberine inhibits the 
production and the expression of mRNA in cells TSLP HMS-1, by carrying out an important role in atopic 
dermatitis, asthma and chronic lung disease  (bronchus obstructive pulmonary disease)[20]. Berberine could be 
a useful support in the treatment of Alzheimer [21]. 
 
Protopine 
 
Registration number: 2086-83-1 
PubChem ID: 2353 
Molecular weight: 336.36122 [g/mol] 
Registration number: 130-86-9 
PubChem ID: 4970 
Molecular weight: 353. 36856 [g/mol] 
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Numerous studies in the literature regarding the effects of protopine, shows that this compound inhibits the 
synthesis of the neurotransmitters serotonin and noradrenaline[22]. It acts as a potent inhibitor of the synthesis 
of thromboxane and has an anti-platelet aggregating action. It shows good anti-inflammatory properties[23]. 
Pre-treatment of the line PC12 with protopine appears to improve cell viability by increasing the activity of 
enzymes superoxide dismutase, catalase and glutathione peroxidase, with a consequent decrease in cells 
damaged by hydrogen peroxide (H2O2). The analgesic action of protopine seems interact to the system of 
calcium and opioids, but also to the adrenergic mechanism[24].  
 
 
Stilopine 
 
 
Stilopine appears to possess anti-inflammatory properties. S.I Jang et al. in 2004[25] conducted a study that 
explains how stilopine may contribute to the anti-inflammatory action of C. majus. The results show that 
stilopine suppresses the production of nitric oxide and prostaglandin E2 in macrophages by inhibiting the 
expression of INOS (inducible nitric oxide synthase) and COX-2 the protein.  
 
Dihydroberberine 
 
Registration number: 130-86-9 
PubChem ID: 4970 
Molecular weight: 353. 36856 [g/mol] 
Registration number: 483-15-8 
PubChem ID: 10217 
Molecular weight: 337.36916 [g/mol] 
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Many literature reports suggest that dihydroberberine may be used as a therapeutic agent in the treatment of 
type 2 diabetes. Indeed it has been reported to reduce the blood glucose both fasting and after the meal, to a 
higher glucose tolerance, alleviates the resistance insulin and lowers blood triglycerides. 
 
Other than a big variety of small molecules, C. majus is also reported to contain a few proteins, which could 
have a potential therapeutic interest. In this context, our interest focused on one of them (Chelidocystatin), 
which is classified as a phytocystatin and consists of  and is a single chain 90 a.a. long (Figure 3,4) It is mostly 
found in the C. majus roots. For this protein inhibition properties for three cystein proteses (among which 
cathepsin L) are reported. 
 
The sequence of Chelidocystatin in reported below: 
 
                     10         20         30         40         50  
             GQFSVDEYNS KNKSNLKLLK VVKAEEQVVA GKKYYLKISA SGKIYDAVVV 
                     60         70         80         90                      
             KKYYLKISAS GKIYDAVVVV KAWETPSKVL VSFDPSTFSQ 
 
 
Figure 3. Amino acid sequence of Chelidocystatin 
 
 
The way the protein can be spatially arranged is shown below (theoretical model obtained by us, as reported 
in one of the following sections)  
 
 
                                         
Figure 4. Molecular structure of Chelidocystatin obtained by homology building  
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Aim of the study 
The aim of this research is the identification of new small molecules acting as inhibitors of Cathepsin L, that is 
recognized to be an important target for anticancer therapies. Indeed Cathpsin L inhibitors are expected to 
elicit their actions against tumor invasion and metastases. In a first stage the research exploits information 
coming from structural studies of complexes between an inhibitor of natural origin (Chelidocystatin) and the 
target biomolecule. Chelidocystatin is a single chain protein 90 a.a. long, obtained from raw extracts of 
Chelidonium majus, which has been shown to inhibit several cathepsins. Beyond its direct use as potential 
anticancer drug, which is strongly hindered by many practical problems, theoretical studies, at the molecular 
level, of interaction between Chelidocystatin and Cathepsins are expected to allow a deep understanding of 
the requirements for activity and selectivity in new synthetic Cathepsin L inhibitors. 
This part of the study is expected to help in designing new more specific and selective small molecules 
endowed with the wanted property. The design work focuses on  
(a)  generating virtual libraries on the basis of already known irreversible inhibitors of Cathepsin L and  
(b)  screening them “in silico” through molecular docking and other computational tools enabling the 
identification of new potential inhibitors. 
The screening carried out “in silico” is expected to suggest a limited number of molecules worth to be 
synthesized and to be subsequently subjected to the experiments needed for validating the predictive work. 
Due to the complexity of the synthetic step, other libraries of commercial compounds or molecules already 
available in our lab become part of the entire pool of compounds virtually screened. 
A straightforward validation of the predictive work would initially suggest to perform simply enzyme inhibition 
assays. Cathepsin L is commonly thought to act in the intracellular compartment, which implies that the 
experimental condition could be easily defined. Nevertheless the importance of Cathepsin L as target for 
antitumor-antimetastatic agent shifts the interest to the actions which it can accomplish outside the cell. 
Because of that a wide spectrum study of Cathepsin L kinetics represents the most important part of the 
experimental validation of the predictive work performed in the research described this thesis.  
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CHAPTER 4 
 
MATERIALS AND METHODS 
 
 
       
 
 
The study described in this thesis started with the selection of a biological target which could be of interest for 
the discovery of new anticancer-antimetastatic drugs, and could also be suitable for accomplishing “in silico” 
the design of new ligands of potential therapeutic interest. Subsequent experiments needed for the validation 
of the computational work had been also planned. The prosecution of the study required that the experiments 
already planned were slightly changed in order to answer to unexpected experimental problems. In this 
chapter we describe the computational and experimental approaches used, as well as the starting points of the 
study. 
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4.1 Approaches Used in the  Computational Study 
A brief overview of some computational approaches commonly required for the design of new ligands of 
macromolecular biological targets is reported below. 
 
4.1.1 Molecular and quantum mechanics. A brief introduction. 
 
The various operations carried out in the molecular modeling procedures. aimed at the drug design, involve 
the use of programs or algorithms which calculate structural features and properties for the system under 
investigation. The computational methods used for such kinds of calculations can be grouped into two 
categories – quantum mechanics and molecular mechanics.  
 
4.1.1.1 Quantum mechanics (QM) 
Quantum mechanics uses quantum physics to calculate the properties of a molecule, where the interaction 
between the electrons and nuclei of the molecule are considered. Unlike molecular mechanics, atoms are not 
treated as solid spheres. To make the calculations feasible, various approximations have to be made. First, 
nuclei are regarded as motion-less. This is reasonable since the motion of the electrons is much faster in 
comparison. Since the electrons move independently from each other the influence of other electrons and 
nuclei is taken as an average. Quantum mechanical methods can be split up, in turn, into two broad groups: 
“ab initio” or semi-empirical methods. The former is more rigorous and does not require any stored parameter 
of experimental origin. However, it is expensive on computer time and its use is restricted to small molecules. 
Semi-empirical methods are faster though less accurate, and can be carried out on larger molecules. The 
reason why these last methods are faster stands in the use of further approximations and stored parameters of 
experimental origin or previously computed “ab initio” on small molecular fragments. More recently other 
approaches (i.e. Density Functional Theory - DFT) were developed, but they can not be exploited yet when 
treating very large systems such as complexes involving proteins and ligands (even consisting of small 
molecules). 
 
4.1.1.2 Molecular mechanics (MM) 
In molecular mechanics (MM), equations are used which follow the laws of classical physics and apply them to 
molecular nuclei without considering their electrons. In essence, the molecule is treated as a series of spheres 
(the atoms) connected by springs (the bonds). Equations derived from classical mechanics are used to 
calculate the different interactions and energies resulting from bond stretching, angle, bending, torsional 
energies, and non-bonded interactions. While QM exploits the Hamiltonian operator to obtain the energy of the 
system under investigation (as above mentioned), the energy function in MM is computed through the so-
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called “force-field”, which consists of an empirical fit to the potential energy surface in which the protein exists 
and is obtained by establishing a model with a combination of bonded terms (bond distances, bond angles, 
torsional angles, etc.) and non-bonded terms (van der Waals and electrostatic). The relative contributions of 
these terms are adjusted for the different types of atoms in the simulated molecule by adjusting a series of 
parameters (see above) The information contained in a force-filed is based on data of experimental origin (in 
the form of parameters) which are stored in tables within the program and which describe interactions between 
different sets of atoms with a certain level of approximation. Such parameters may be experimentally 
estimated or calibrated by means of more accurate QM calculation of molecular fragments, under the further 
approximation that their contribution may be simply added to one another. Consequently, the energies 
calculated by molecular mechanics have no meaning as absolute quantities but are useful when comparing 
different conformations of the same molecule. Molecular mechanics is much faster and less expensive on 
computer time than quantum mechanics. However, it cannot calculate electronic properties since electrons are 
not included in the calculations.  
 
4.1.1.3 Energy minimization 
The process of simulating “in silico” three-dimensional (3D) structures of biological macromolecules by means 
of molecular graphics necessarily leads initially to unfavorable interactions (not appropriate bond lengths, bond 
angles or torsion angles). Unfavorable non-bonded interactions may be also present (i.e. atoms from different 
parts of the molecule may occupy overlapping regions of space). The energy minimization process is usually 
carried out by a molecular mechanics program which calculates the energy of a starting atomic configuration 
for the molecule of interest. Then bond lengths, bond angles, and torsion angles are changed and optimized 
on the basis of energy minimization algorithms. Often the starting structure is inherently unstable; a slight 
alteration in bond angle or bond length will have a large effect on the overall energy of the molecule, mostly 
resulting in significant energy difference (E). The procedure goes ahead until changes in the atom 
configuration only causes very small changes in the energy values. The procedure will interpret such a 
conformations as a stable structure and will stop at that stage. Energy minimization is carried out to produce a 
stable conformation for a 3D structure. However, the structure obtained is not necessarily the most stable 
conformation. This is because the energy minimization stops as soon as it reaches the first stable 
conformation it finds, (local energy minimun).  
 
 
 
 
Figure 1. 1D schematic representation of multidimensional space. 
 coordinate 
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This can be illustrated in a schematic mono-dimensional (1D) representation (figure 1) in which different 
energy minima are separated from each other by energy barriers of differnet heights which the algorithm 
doesn’t allow to overcome If the starting 3D structure is on the energy curve  at the position shown by the star, 
energy minimization will stop when it reaches the first stable conformation it encounters (a local energy 
minimum). When we goes to systems represented in 3D the energy profile of the system, represented in a 
fourth dimension as a function of the spatial coordinates (x, y, z), is usually referred as an “energy hyper-
surface”. On this hyper-surface the barriers may correspond to hills or to saddles.  
 
4.1.1.4 Molecular dynamic simulations 
Within the Molecular Dynamics (MD) approaches the generation of a variety of different conformations is 
allowed by different molecular dynamics simulation algorithms which are able to ‘heat’ the molecule to high 
temperatures (usually up to 800-900 K). It means that the program allows the structure to undergo bond 
stretching and bond rotation as if it was being heated. As a results, energy barriers between different 
conformations may be overcome, allowing the system to cross them. In the process, the molecule is heated at 
a high T (900 K) for a time range (e.g 5 picoseconds), then cooled to 300 K for another time range (e.g. 10 ps) 
to give a final structure. The process can be repeated automatically as many times as wished to give as many 
different structures as required. Each of these structures can then be collected, energy minimized and simple 
components of its energy can be estimated. By carrying out this procedure, it is usually possible to identify 
distinct conformations, some of which might be more stable than the initial conformation. 
Another interesting feature emerging from the use of MD simulations is that from a large ensemble of sampled 
structures and their associated potential energies it is, in principle, possible to estimate free energies. 
Quantities such as binding free energies (G), solvation free energies and activation free energies are 
particularly interesting to be estimated because they can be correlated to the results of thermodynamic or 
kinetic experiments. It is thus possible to quantitatively compare calculated quantities  against experimental 
data so that models of biological systems may be validated and then exploited to make predictions(46) 
 
4.1.1.5 Molecular docking calculations 
The Molecular Docking methods enable to optimize orientations and conformations small molecules within the 
binding site of a given biological macromolecular target, provided that its 3D structure can be modeled with the 
needed accuracy. It is frequently used to predict the binding capabilities of drug candidates. The interaction 
energy are computed through quite fast methods (usually much faster in comparison with MM - see later on), 
which allow to predict the relative affinity of a set of small molecules toward a receptor or they ability of 
inhibiting an enzyme. 
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The application of computational methods to study the formation of intermolecular complexes has been the 
subject of intensive research during the last decade. It is widely accepted that drug activity is obtained through 
the molecular binding of one molecule (the ligand) to the pocket of another, usually larger, molecule (the 
biological macromolecular target), which is commonly a protein. In their binding conformations, the molecules 
exhibit geometric and chemical complementarity, both of which are essential for successful drug activity. The 
computational process of searching for a ligand that is able to fit both geometrically and energetically the 
binding site of a protein is called molecular docking. 
In the context of docking, energy evaluations are usually carried out with the help of a scoring function. The 
two main characteristics of a good scoring function are selectivity and efficiency. Selectivity enables the 
function to distinguish between correctly and incorrectly docked structures and efficiency enables the docking 
program to run in a reasonable amount of time, as the advantage afforded by the molecular docking 
approaches in drug design relay in the possibility of screening a very large amount of small molecules. A large 
number of current scoring functions are based on force-fields that were initially designed to estimate several 
properties of of proteins[2,3]. Some scoring functions used in molecular docking have been adapted to include 
terms such as solvation and entropy[4]. Most of the docking methods used at the present moment in academic 
and industrial research all assume a rigid protein.  
In the study described here, the Autodock 4.2 program was used [4]. In Autodock, the ligand begins the search 
process randomly outside the binding site and by exploring the values for translations, rotations and its internal 
degrees of freedom, it will eventually reach the bound conformation. Distinction between good and bad docked 
conformations is carried out by the scoring function. Autodock is able to use Monte Carlo methods or 
simulated annealing (SA) in the search process and in its most recent version introduced the ability to use 
genetic algorithms (GA). The routine implemented in the recent release is a Lamarkian genetic algorithm 
(LGA), in which a traditional GA is used for global search and is combined with a Solis and Wets [7] local 
search procedure. Morris et. al.[4] show that the new LGA is able to handle ligands with a larger number of 
degrees of freedom than SA or traditional GA. 
 
4.1.2 Cathepsin L Natural Inhibitors 
4.1.2.1  Cystatin B 
The 3D structures of a Cathepsin L-Stefin A complex and a Papain-Stefin B complex were downloaded from 
PDB (IDs: 3KSE and 1STF, respectively). Due to similarity between stefinA and stefinB the scaffold of the 
Cathepsin L-Stefin A complex was used to obtain an initial putative Cathepsin L-Stefin B complex by 
superimposing Stefin B on Stefin A. The initial complex so obtained was subjected to geometry optimization by 
minimizing its energy through Molecular Mechanics (MM) calculations in order to smooth bad contacts arising 
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from the superimpositions of the two inhibitors.  Geometrical optimization was followed by structural/energetic 
analysis. That enabled preliminary observations about features responsible for the activity of the protein acting 
as inhibitor of natural origin (Chelidocystatin) which is of interest for us.  
 
4.1.2.3 Chelidocystatin 
The 3D structures of Cathepsin L (CAL), Cathepsin H (CAH) and Papain (PAP) were downloaded from PDB 
(IDs: 1ICF, 1NB5 and 1STF, respectively). A 3D model of Chelidocistatin (CHE) (sequence ID on Swiss-Prot 
Database: Q8GZV2) was built on the bases of its high sequence similarity with Oryzacystatin-I (ORY) (PDB ID: 
1EQK), another cysteine proteinase inhibitor coming from rice. The model, based on the sequence alignment 
reported in Figure 2, was obtained through the Swissmodel server (http://swissmodel.expasy.org/). 
 
 
 
Figure 2. Sequence alignment between Chelido-cystatin (target) and Oryza-cystatin (1eqk). Identities: 34.4 %. The 
residues evidenced in yellow are believed to be involved in the inhibitory activity and are highly conserved in the cystatin 
superfamily. 
 
Due to similarity between CHE and Stefin B (STE) (ID:1STF), that also belongs to the cystatine superfamily, 
the scaffold of a PAP-STE complex was used to obtain an initial putative PAP-CHE complex. The highly 
conserved sequence “QVVAG” plus residue “G3” were used for the superimposition of the CHE model on the 
STE molecule so obtaining the PAP-CHE complex. CHE-CAH and CHE-CAL complexes were then obtained, 
by superimposing the two proteins on the PAP molecule in the first complex. All the complexes were submitted 
to geometry optimization by minimizing Molecular Mechanics (MM) energy in order to smooth bad contacts 
arising from superimpositions.  
Geometrical optimization was followed by structural/energetic analysis. That enabled preliminary observations 
about features responsible for the activity of CHE on its targets.  
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4.1.3 The Molecules subjected to virtual screening 
Two virtual libraries of potential inhibitors were initially designed on the basis of preliminary SAR studies (see 
table 1-2). A further library of commercial compounds was then considered for being subjected to the virtual 
screening (see Table 3). In addition, other compounds available in our laboratories were then subjected to the 
same screening (see Table 4). Finally some alkaloids contained in C. Majus and know to act as anticancer 
agents were included in the screening (see table 5). 
 
4.1.3.1 Design of Cathepsin L irreversible inhibition 
4.1.3.1.1 Building of a virtual library 
A first virtual library of potential inhibitors of Cathepsin L was built starting from the molecular scaffold shown in 
Figure 3. Its structure was suggested on the basis of known Cathepsin L inhibitors reported in the literature, 
through rough SAR analysis[1]. The scaffold was used for designing a series of analogs obtained by changing 
the R1, R2 and R3 substituents.  
 
The compound comprised in the first virtual library are reported in table 2 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  The scaffold shown in figure was chosen  as the starting point in order to ensure to the newly designed molecules two possible points 
for the interaction with the Cys25 residue of the protein binding site. The sub-sites for the global ligand anchoring to the protein pockets, 
represented by R1, R2 and R3, refer to the moieties that are to be changed for ligand structure optimization in order to increase the inhibition 
capability of these derivates toward cathepsinL. 
 
 
 
 
R1
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ID R1 R2 
Aziridide 
Config 
R3 
 
CR1 
 
Bn S,S (S)-Azy-(S)-Leu 
CR2 
 
CH2-Bn S,S (S)-Azy-(S)-Leu 
CR3 
 
CH2-Bn S,S (S)-Azy-(S)-Leu 
CR4 
 
CH2-Bn S,S (S)-Azy-(S)-Leu 
CR5 
 
CH2-Bn S,S (S)-Azy-(S)-Leu 
CR6 
 
CH2-Bn S,S (S)-Azy-(S)-Leu 
CR7 
 
CH2-Bn S,S (S)-Azy-(S)-Leu 
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CR8 
 
CH2-Bn S,S (S)-Azy-(S)-Leu 
CR9 
 
CH2-Bn S,S (S)-Azy-(S)-Leu 
CR10 
 
CH2-Bn S,S (S)-Azy-(S)-Leu 
CR11 
Me
 
CH2-Bn S,S (S)-Azy-(S)-Leu 
CR12 Bn 
 
S,S (S)-Azy-(S)-Leu 
CR13 CH2-Bn 
 
S,S (S)-Azy-(S)-Leu 
CR14 CH2-Bn 
 
S,S (S)-Azy-(S)-Leu 
CR15 CH2-Bn 
 
S,S (S)-Azy-(S)-Leu 
CR16 CH2-Bn 
 
S,S (S)-Azy-(S)-Leu 
CR17 CH2-Bn 
 
S,S (S)-Azy-(S)-Leu 
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Table 1.  
 
The importance of the first library was more speculative than applicative, as the compounds were conceived in 
order to enable an exhaustive exploration of the binding potential of new small ligands. During a feasibility 
study for the subsequent synthetic work, conducted in parallel with the computational work, the compounds 
included in this library appeared to be quite complex to be synthesized. Because of that, the subsequent step 
implied the design of a virtual library containing compounds easier to be synthesized, although less rich in 
structural diversity. They are reported in table 3. 
 
 
 
 
 
CR18 CH2-Bn 
 
S,S (S)-Azy-(S)-Leu 
CR19 CH2-Bn 
 
S,S (S)-Azy-(S)-Leu 
CR20 CH2-Bn 
 
S,S (S)-Azy-(S)-Leu 
CR21 CH2-Bn 
 
S,S (S)-Azy-(S)-Leu 
CR22 CH2-Bn 
Me
 
S,S (S)-Azy-(S)-Leu 
CR23 CH2-Bn 
 
S,S (S)-Azy-(S)-Leu 
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Table 2.  Compounds added to the initial library. 
 
 
                                                              
Compound R1 R2 
Aziridide 
Configuration 
R3 
CR24 
 
 S,S 
N C(CH3)3
NH2
O
 
CR25 
 
 
S,S 
NH2
NH2
 
CR26 
  
S,S 
NH2
NH2
 
CR27   S,S 
NH2
NH2 
CR28   S,S 
NH2
 
CR29   S,R 
NH2
 
CR30   S,R 
NH2
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4.1.2.2 Commercial ligands 
In order to speed up the acquisition of preliminary results enabling to better address the research, available 
commercial ligands were selected using similarity criteria with respect to the compounds contained in the 
above virtual libraries, where the aziridine ring is included, as shown in figure 2. Their CAS numbers and 
structures were reported in table 4. 
 
 
CAS 
number 
Structure CAS number Structure 
66701-25-5 
(E64) 
 
16466-61-8 
 
 
 
76684-89-4 
(E64c) 
 
17696-94-5 
 
 
 
88321-09-9 
(E64d) 
 
21384-57-6 
 
4114-28-7 
 
84315-89-9 
 
 
   Table 3.              
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3.1.2.3 Other simpler aziridine derivatives 
Other aziridine derivatives, even simpler and already available in the laboratory directed by Prof. M. Pineschi 
at the Departement of Pharmaceutical Science (University of Pisa) were also considered. Their scaffold, is 
similar to the template used in the design of the above libraries. In spite their quite poor drug-likeness 
properties, their interest could rely in the possibility of finding “hit” molecules to be subsequently modified in 
order to achieve our purposes. Their structures are reported in table 5. 
 
Compound Structure Compound Structure 
Az1 
 
Az9 
 
Az2 
 
Az10 
 
Az3 
 
Az11 
 
Az4 
 
Az12 
 
Az5 
 
Az13 
 
Chapter 4 
 
Page 62 
 
Az6 
 
Az14 
 
Az7 
 
Az15 
 
Az8 
 
 
 
Table 4.  
 
4.1.1.3 Alkaloids from Chelidonium majus 
The major mechanism by which Chelidonium majus alkaloids are considered to act in relation to their 
anticancer activity is the interference with the dynamic tubuline polymerization-depolymerization equilibrium. 
Nevertheless alternative mechanisms could also be hypothesized for some of these alkaloids, for which  
experiments on several different cell lines had previously suggested a significant anticancer activity. In order to 
have a deeper insight on these mechanisms, some of the alkaloids contained in Chelidonium majus were 
screened “in silico” against Cathepsin L. The these alkaloids are reported in table 1. 
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Name Structure Name Structure 
Berberine 
 
Dihydroberberine 
 
Canadine 
 
Protopine 
 
Chelerythrine 
 
Stylopine 
 
Coptisine 
 
  
Table 5: The alkaloids from Chelidonium majus analyzed for their inhibitory activity toward Cathepsin L. 
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4.1.3.6 Autodock settings. 
A starting 3D model of Cathepsin L was build based on the 3D structure taken from PDB (ID: 3HHA). The 
structures of all molecules comprised in the libraries reported above were built by using the Vega ZZ program5; 
they were then subjected to automated docking, which was performed by the molecular docking software 
AutoDock 4.0[6]. An already know compound (AZ12878487 that is the ligand crystallized in the 3HHA structure) 
was also subjected to the same docking protocol in order to accomplish a preliminary validation step for the 
theoretical model of the ligand-cathpsin system, by structural analysis and comparison with literature data. 
Molecular docking of all the structures in the cathepsin L binding site produced several orientations and 
conformations for each ligand. For each one of them, the best scoring conformation was selected. Partial 
atomic charges were determined by the Gasteiger method and rotatable bonds were assigned through Auto 
Dock Tools. Prior to the AutoDock, AutoGrid calculations were performed so obtaining a required grid map 
which defines the simulation space. A grid box with a number of points in xyz (npts) of 50-50-60 Å was used. 
The box spacing was 0.375 Å and the grid was set in order to cover the entire space of the binding site. A 
distance-dependent function of the dielectric constant was used for the calculation of the energetic maps. 
Finally, AutoDock was run using the maximum number of energy evaluations retries and generations of 10000 
and 27000, respectively. The Lamarckian genetic algorithm (LGA) with the pseudo-Solis and Wets 
modification (LGA/pSW) method was used with default parameters for calculation of the docking possibilities.  
 
4.1.3.7  NAMD settings. 
Molecular Dynamic Simulations were performed on the complexes of Cathepsin L with three ligands, identified 
as the most promising ones among all the compounds investigated (CR29 ,CR30 and CR26, see Table 1). 
The NAMD[8] molecular dynamics simulation code and CHARMM22 force field with an explicit solvent 
representation were used. Each ligand-protein complex was embedded in a TIP3P water solvent sphere using 
the solvate routine. The systems were subjected to energy minimization using conjugate gradient 
minimization. Then, the systems were gradually heated from temperature T = 0 K to T = 300 K over 10 ps. 
Then Langevin dynamics at 300 K were performed for a total of other 500 ps. Energy equilibrium was reached 
after approximately 100 ps for CR29-/CR26-cathepsin L complex and 150 ps for CR30-cathepsinL complex . 
All simulations used a time step of 1 fs.  
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4.2 Kinetic Study 
Initially, only experiments aimed at measuring the potential inhibition of some compounds, selected among the 
ones previously subjected to virtual screening, were planned. This is the straightforward protocol which must 
be followed for validating the predictive study accomplished “in silico”. Subsequently, the need of performing a 
characterization of the enzyme kinetics of the human Cathepsin L in different experimental conditions 
appeared to be mandatory, as a preliminary study. Indeed different roles of Cathepsin L in different 
compartment of living organisms are being proposed in the most recent literature reports. In this perspective 
the conditions in which the inhibition experiments planned for the identification of new potential anticancer 
drugs would have reasonably to be investigated in more depth. In this work, the kinetics of the 29 kDa form of 
the human liver cathepsin L (hereinafter “cathepsin L”) binding to its substrate Z-Phe-Arg 7-amido-4-
methylcoumarin hydrochloride (Z-Phe-Arg-AMC) was studied by modifying some environment parameters, in 
order to simulate various cellular compartments and to explore how the kinetics of this enzyme may change in 
different biological conditions. 
 
4.2.1 Methods 
The enzymatic reaction was investigated by carrying out the assays under different conditions and by using 
different concentrations of several physiological modulators, such as (a) the selected substrate Z-Phe-Arg-
AMC, (b) pH, (c) endogenous inhibitor cystatin B, (d) copper, iron and zinc ions, and (e) cysteine. These 
experiments were expected to help in understanding how the above mentioned environmental parameters 
affect the kinetics of the enzymatic reaction. 
The general protocol for the enzymatic assay is based on the detection of the release of the fluorophore 
aminomethylcoumarin (AMC), upon enzymatic hydrolysis, from the above mentioned dipeptide labelled with 
AMC. The assay buffer consisted of 20 mM sodium acetate, under the varying concentrations of said 
physiological modulators, as specified below. The enzymatic reaction was monitored by using an Envision 
fluorescent microplate reader (PerkinElmer Life and Analytical Sciences, Waltham, MA, USA), and the 
fluorescence signal was measured at the excitation and emission wavelengths of 355 and 460 nm, 
respectively. 
The details about the experiments carried out for this research are reported below: 
 
(a) in a first pool of experiments, aimed at analysing the effect of substrate concentration in a lysosomal 
reducing environment, the assay was carried out using 1.25, 0.62, 0.33 µM of Z-Phe-Arg-7-amino-4-
methylcoumarin (Z-Phe-Arg-AMC), 0.5 µg/ml human liver cathepsin L (Calbiochem), 1 mM EDTA and 
5 mM cysteine in 20 mM sodium acetate buffer, pH 5.5. The enzyme was pre-incubated in buffer for 1 
h to ensure that the catalytic cysteine was in the reduced form; 
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(b) in a second pool of experiments, aimed at analysing the effect of pH in a reducing environment,. 
several pH values were selected, based on the pH values which are significant at the cellular level: 
pH=5.5 simulating the lysosomal compartment, pH=7.4 typical of the extracellular fluids, pH=6.4 
simulating the cell nucleus, and other more acidic values. The enzymatic reaction was carried out at 
37°C, in 20 mM sodium acetate buffer, in the presence of 1 mM EDTA and 5 mM cysteine. The 
enzyme was pre-incubated in buffer for 1 h to ensure that the catalytic cysteine was in the reduced 
form; 
 
(c) in a third pool of experiments, aimed at analysing the effect of the endogenous inhibitor cystatin B in a 
reducing extracellular environment, several cystatin B concentrations were tested. The enzymatic 
reaction was monitored at 37°C, in 20 mM sodium acetate buffer, pH 7.4, in the presence of 1 mM 
EDTA and 5 mM cysteine. The enzyme was pre-incubated in buffer for 1 h to ensure that the catalytic 
cysteine was in the reduced form; 
 
(d) in a fourth pool of experiments, aimed at analysing the effect of metal ions in a not-reducing 
extracellular environment, three metal ions (copper, iron, and zinc) were tested, since they are 
normally found in extracellular fluids. For each one of them, three concentrations were investigated 
(the physiological concentration, a metal excess leading to toxicity, and a metal concentration 
corresponding to deficiency condition). The enzymatic reaction was monitored at 37°C, in 20 mM 
sodium acetate buffer, in the absence of EDTA and cysteine. 
 
The experiments described in this Chapter were aimed at characterizing and understanding the behavior of 
the Human Liver Cathepsin L supplied by Calbiochem. To reach this goal, the stability and catalytic activity of 
this enzyme were investigated under different conditions, such as: 
- non-reducing conditions and at a pH of 7.4, in order to simulate the extracellular compartment; 
- in the presence of several metal ions, such as iron, zinc and cupper; 
- in the presence of the natural modulator/inhibitor Stefin B (Cystatin B). 
 
Data resulting from these experiments provided interesting information which allowed us to better understand 
the potentiality of Cathepsin L in playing a role at the extracellular level. Moreover, such data provided us with 
a good basis to draw a mechanistic model which would allow the interpretation of Cathepsin L behavior in 
different surroundings and be a useful tool in the screening of candidate modulators of this enzyme. 
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4.2.2 Materials 
Human Liver Cathepsin L was purchased from Calbiochem (Cat. 219402) in amount of 25 µg in 400 mM NaCl, 
20 mM malonate buffer, 1 mM EDTA, pH 5.5. 
The substrate Z-Phe-Arg-AMC (Z-Phe-Arg 7-amido-4-methylcoumarin hydrochloride) was purchased from 
Sigma Aldrich (Cat. C9521). 
Other materials exploited: 
SIGMA Acetic Acid , Glacial 99,99% Lot# 02596M Cod. 338826 25 ml 
SIGMA L-Cysteina Bioultra Lot# BCBD3830V Cod. 30089  25 mg 
SIGMA EDTA Disodium Salt Dihydrate Lot# 91K0133 Cod. E-5134 100 g 
SIGMA E-64c (2S,3S)-trans-Epoxysuccinyl-L-leucylamido-3-methylbutane Cod. E0514-1MG  
Salts of copper, zinc and iron have been taken in the laboratory of synthesis. 
All technique were performed with fluorescence (Ex 355 Em 460) in 96-well plates (Sarstedt Tissue Culture 
Plate 96-well flat botton cell +) to the dark background. All buffers were prepared strictly in volumetric flasks 
and brought to volume. For the preparation of the enzyme have been made from 2 l aliquots and kept at -80 ° 
C, once it is carried out the experiment is taken an eppendorf thawed and diluted with the buffer for the 
experiment, this in turn is held at -20 ° C. The substrate is prepared at various concentrations by a mother in 
highest concentration and by subsequent dilution and then held at -20 ° C. All solutions are prepared using 
Gilson (Gilson Pipetman ® P) 100, 200, 20 and 2µl. 
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5.1 Cathepsin L natural inhibitors 
5.1.1 Stefin B  
The research started with molecular modelling studies that supplied a plausible theoretical model of the 
complex between cathepsin L and one of its endogenous  inhibitors, Stefin B. Due to similarity between stefin 
A and stefin B the scaffold of the Cathepsin L-StefinA complex was used to obtain an initial putative Cathepsin 
L-Stefin B complex by superimposing Stefin B on Stefin A. In particular the highly conserved sequence 
“QVVAG” (considered crucial for interactions of the natural reversible inhibitors of cysteine proteinases) was 
used for the superimposition. The initial complex so obtained was submitted to geometry optimization by 
minimizing Molecular Mechanics (MM) energy in order to smooth bad contacts arising from superimpositions. 
Their final structure is shown in Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Molecular structure of the optimized complex involving Cathepsin L (red) and Stefin B (blu). 
 
Geometrical optimization was followed by structural/energetic analysis performed on the InterProSurf web 
server (http://curie.utmb.edu)[1]. That enabled preliminary observations about features responsible for the 
activity of the natural inhibitor of our main interest, Chelidocystatin, on its target.  
 
Complex Contact 
Area (Å2) 
Stefin B residues at the 
interface 
Protein Residues at the 
interface 
Cat L- Stefin B 2204.38 19 (including QVVA sequence) 27 
 
Table 1. Interfaces ana1ysis the complex involving Cathepsin L and Stefin B. 
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Cathepsin L and Stefin B in the theoretic model of the complex show good “contact area” and a high number 
of residues at the interface so highlighting a tight interaction between the partners. This observation allows us 
to explain the inhibitory property of Stefin B toward Cathepsin L, as already reported in the literature and 
subsequently measured by us in specific experimental conditions (see later). It may be worth to highlight here 
that the QVVA sequence of Stefin B, the one reported to be crucial for the inhibitory activity, presents an high 
number of  interactions with the partner protein (See Table 2).  
 
Stefin B QVVA sequence Interacting residues in cathepsin L 
GLN53 Gly23, Cys65, Asn66 
VAL54 Gln19,  Gly23, Cys25, Asp162, His163 
VAL55 Gln19,  Gly 20, Gln21, Gly23 
ALA56 Gly 20, Gln21 
 
Table 2. Interactions occurring between QVVA sequence of Stefin B and some residues of cathepsin L in the theoretical optimized complex. 
 
5.1.2 Chelidocystatin 
Molecular modelling studies of complexes between the selected biomolecular target (Cathepsin L) and 
Chelidocystatin were then undertaken. A 3D model of Chelidocystatin was built on the bases of its high 
sequence similarity with Oryzacystatin-I.  Due to similarity between Chelidocystatin and Stefin B, which also 
belongs to the cystatin superfamily, the scaffold of a Papain-Stefin complex was used to obtain an initial 
putative Papain-Chelidocystatin complex. The highly conserved sequence “QVVAG” plus residue “G3” were 
used for the superimposition of Chelicystatin model on the Stefin molecule so obtaining the Papain-
Chelidocystatin complex. Chelidocystatin-Cathepsin H and Chelidocystatin-Cathepsin L complexes were then 
obtained, by superimposing the two proteins on the PAP molecule in the first complex. All the complexes were 
submitted to geometry optimization by minimizing Molecular Mechanics (MM) energy in order to smooth bad 
contacts arising from superimpositions. Their final structures are shown in Figure 2. 
 
 
 
 
 
 
 
Figure 2:  Molecular structures of the optimized complexes involving chelidocystatin and a) cathepsinL, b) cathepsinH, c) papain, respectively. 
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Structure analysis was performed on the Chelidocystatin-Cathepsin L, Papain-Chelidocystatin and 
Chelidocystatin-Cathepsin H complexes in order to identify features responsible for the interaction of 
Chelidocystatin with such proteins. In particular, interfaces between the partners in the complexes were 
analyzed. The Chelidocystatin-Cathepsin L and the Papain-Chelidocystatin complexes show bigger “contact 
area” and higher total number of “contacts”, so highlighting a tighter interaction between the partners in 
comparison with the Cathepsin H - Chelidocystatin one (See Table. 3).  
 
 
Complex 
Contact 
Area (Å2) 
Chelidocystatin residues at 
the interface 
Protein Residues 
at the interface 
Number of 
contacts 
Exp. Ki (M) 
catL-chelido 3143 11 (including QVVA sequence) 20 407 5.60E-11 
Papain-chelido 3181 10 (including QVVA sequence) 19 409 1.10E-10 
catH-chelido 3043 12 (including QVVA sequence) 22 392 7.50E-09 
 
Table 3. Interfaces ana1ysis and experimental affinity data for the three complexes. 
 
In particular, the QVVA sequence of Chelidocystatin, reported to be crucial for the inhibitory activity, presents 
more interactions with the partner protein in the first two complexes (See Table 4).  
 
Chelidocystatin 
QVVA sequence 
Interacting residues in 
cathepsin L 
Interacting residues in 
Papain 
Interacting residues in 
cathepsin H 
GLN46 Gly23, Cys65, Asn66 Gly23, Cys63, Asn64 Gly23, Cys63, Gln64 
VAL47 
Gln19,  Gly23, Cys25, Asp162, 
His163 
Gln19,  Gly23, Asp158, 
His159, Trp177 
Gly23, Cys25, Asn158, His159 
VAL48 
Gln19,  Gly 20, Gln21, Cys22, 
Gly23 
Gln19,  Gly 20, Ser21, 
Cys22, Gly23, Trp177 
Gln19,  Ser21, Cys22, Gly23, 
Trp177 
ALA49 Gly 20, Gln21 Gly 20 Gly 20 
 
Table 4. Interactions occurring between QVVA sequence of chelidocystatin and some residues of the partner proteins in the relevant complexes. 
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These results are in agreement with experimental data9. Starting from the analysis of the interaction of 
Chelidocystatin with Cathepsin L, a suggestion enabling the design of small peptidic or small peptidomimetic 
inhibitors could be obtained in future studies.   
 
5.1.3 Alkaloids from Chelidonium majus 
In a previous study of us some fractions of Chelidonium majus extracts were shown to possess inhibitory 
activity on different cancer cell lines. In order to identify, among the many compounds contained in the 
extracts, the ones accounting for such an activity, a number of alkaloids contained in the extracts were 
subjected to inhibition assays using the same cancer cell lines. Moreover the results of inhibition of cell 
proliferation caused by other alkaloids contained in C. majus are reported in the N.I.H. databases. The 
alkaloids which appeared of higher interest for our purposes were submitted to the same molecular docking 
protocol, in order to find out if the anticancer activity observed in cells could be due to Cathespin L inhibition. 
The results of these studies are reported in Table 5. 
 
Compound Ebind (Kcal/mol) Hydrogen Bonds 
Chelerythrine -6.63 Cys25 
Stylopine -7.09 
Cys25 
Asp162 
Canadine -6.54 
Cys25 
Asp162 
Dihydroberberine -6.59 Cys25 
Coptisine -5.86 Cys25 
Berberine -5.89 Cys25 
 
Table 5. Results referring to the best scoring pose of each compound. Intermolecular hydrogen bonds and interaction energies (Ebind) were shown.  
 
The results reported in table 5 suggest that all these derivatives can interact with Cathepsin L in a comparable 
amount. Nevertheless, experimental results collected later on, and reported in section 6, showed that  
chelerythrine, coptisine and berberine should be able, instead, to inhibit Cathepsin L in a more significant 
manner with respect to the other derivatives. In order to settle these controversial findings, the analysis of the 
binding mode of these ligands was accomplished in more depth. The results are reported in table 6 
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 Ligand efficiency 
Intermol 
energy 
Vdw hb 
desolv 
energy 
Electrostatic 
energy 
Total 
internal 
Torsional 
energy 
Unbound 
energy 
Dihydroberberine -0.26 -7.19 -6.21 -0.98 0.08 0.6 -0.08 
Stylopine -0.3 -7.09 -5.17 -1.92 0 0 0 
Protopine -0.27 -6.97 -6.4 -0.57 0 0 0 
Berberine -0.24 -6.49 -6.44 -0.06 -0.19 0.6 -0.19 
Coptisine -0.24 -5.86 -5.78 -0.08 0 0 0 
Chelerythrine -0.26 -7.26 -7.15 -0.11 -0.24 0.6 -0.24 
Canadine -0.26 -7.14 -6.19 -0.95 -0.08 0.6 0.08 
 
Table 6. Energetic terms referred to the docked compounds. 
 
The biggest differences in the energetic contributions between chelerythrine, coptisine and berberine with 
respect to the other ligands concern the electrostatic energy term. In the three derivatives, which were 
experimentally found to most active, this term takes the highest values. Probably, such a contribution, mainly 
responsible for the activity, is underestimated by the software in the case of these specific ligands.  
Figures 3 - 8 show the best pose for each docked compound in the Cathepsin L binding site. All the tested 
compound show a good complementarity with the binding site. 
 
 
 
 
 
 
 
 
 
 
Figure 3. Best pose of Chelerythrine  in the cathepsin L binding poket. 
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Figure 4. Best pose of Stylopine  in the cathepsin L binding poket. 
 
 
 
 
 
 
 
 
 
 
Figure 5. Best pose of Canadine in the cathepsin L binding poket. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Best pose of Dihydroberberine  in the cathepsin L binding poket. 
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Figure 7. Best pose of Coptisine  in the cathepsin L binding poket. 
 
 
 
 
 
 
 
 
 
 
Figure 8. Best pose of Berberine  in the cathepsin L binding poket. 
 
After the more accurate structural analyisis, we observed that some of the alkaloids submitted to the molecular 
docking showed a quite good probability to interact with Cathepsin L. They appear to be able of only engaging  
non-covalent bonds with the residues of the Cathepsin L binding site. That suggests a profile of reversible 
inhibitors. As already mentioned above, subsequent experimental results (see later) confirmed the expected 
activity at least for some of them. 
 
5.2 Catepsin L irreversibile inhibition 
5.2.1 Newly designed compounds 
According to studies available in the literature, and concerning synthetic inhibitors for human Cathepsin L, 
such ligands engage a covalent bond with the sulfur atom of Cys25 in the protein binding site. These inhibitors 
are characterized by the presence of moieties required for ligand anchoring. The action mechanism of 
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inhibition is still unclear; at present ligands are thought to be allocated in the binding site through non-covalent 
interactions at first and, once they are correctly allocated, the covalent bond with Cys25 is created. The 
scaffold reported in figure 2, chapter 4, was used for designing a series of analogs obtained by changing the 
R1, R2 and R3 substituents. At a first stage of the research only the R1 and R2 substituents shown in figure 2, 
chapter 4, were changed. Before proceeding at the virtual screening of using molecular docking to evaluate 
the compounds of the library we check the performance of the program in the reproduction of  experimental 
data. In particular, the AZ12878478 ligand (co-cristallized with cathepsin L in the 3HHA structure) were 
submitted to the docking protocol.  The best scoring docked pose  of AZ12878478 ligand was  in good 
agreement with the experimental one being 1.53 Å the RMS between the two structures. See Figure 9.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. The best scoring docked pose  (green) of AZ12878478 ligand was  in good agreement with the experimental one (red). 
 
All compounds comprised in the virtual library were screened for their affinity toward Cathepsin L through the 
sane protocol. For evaluation of the best scoring compounds intermolecular hydrogen bonds and interaction 
energies were taken into account (Table 7). For comparison also the data referred to the AZ12878478 ligand 
are reported in the table. In Figure  10, one of the best scoring compound is shown.  
 
 
 
 
 
 
Red: crystallographic pose of 
the AZ12878478 ligand 
(3HHA.pdb). 
Green: best scoring pose of 
the AZ12878478 ligand. 
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Comp. 
Ebind 
(Kcal/mol) 
D 
[Å] 
Hydrogen 
Bonds 
Comp. 
Ebind 
(Kcal/mol) 
D 
[Å] 
Hydrogen 
Bonds 
CR1 -8.25 4.03 Cys25 CR13 -8.81 4 
2 Cys25 
Gln19 
Asn66 
CR2 -8.49 3.5 
2 Cys25 
Gln19 
CR14 -7.93 3.6 / 
CR3 -7.89 3.1 Gly68 CR15 -7.93 3.8 Cys25 
CR4 -8.21 3.04 
Cys25 
Gly68 
CR16 -7.35 3.9 2 Cys25 
CR5 -7.53 3.34 
Gln19 
Cys25 
Gly68 
CR17 -9.31 3.6 / 
CR6 -8.57 3.5 
Cys25 
Gly68 
CR18 -8.39 3.5 Gln19 
CR7 -8.96 3.17 
Gln19 
Gly68 
CR19 -7.23 3.5 / 
CR8 -7.41 3.18 
Gln19 
Gly68 
CR20 -8.39 3.8 Gln19 
CR9 -8.02 3.6 
Gly68 
Gln19 
CR21 -9.06 4.8 / 
CR10 -9.51 5 
Cys25 
Gln19 
CR22 -7.26 3.5 / 
CR11 -7.57 3.4 / CR23 -9.75 8.5 Asp160 
CR12 -9.28 3.3 Gln19 AZ12878478 -7.65 5.3 Gly68 
 
Table 7. Results referring to the best scoring compounds. For the evaluation of the best scoring compounds intermolecular hydrogen bonds and 
interaction energies (Ebind) were taken into account. The distance (D) to CYS25 residue was also reported.   
 
Chapter 5 
 
Page 78 
 
                                    
 
Figure 10: CR10 ligand in the cathepsin L binding poket. 
 
The results of molecular docking are reported in Table 5, where interaction energies, computed through the 
docking scoring functions, are shown together with hydrogen bonds formed between the best pose for each 
compound and Cathepsin L, estimated by docking calculations, and the distances between the nearest C 
atoms of the aziridine group of the ligand and the S atom of CYS25 in the macromolecular target. 
In order to estimate the synthetic feasibility of the best scoring virtual ligands, a predictor of Synthetic 
Accessibility was used  (http://www.molecular-networks.com/online_demos/sylvia/wsDispatcher.py) The 
predicted indexes for  Synthetic Accessibility for the compounds of the initial library are reported in table 8. 
 
Compound Structure Synthetic Accessibility 
CR1 
 
7.29 
CR2 
 
7.31 
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CR3 
 
7.37 
CR4 
 
7.32 
CR5 
 
7.4 
CR6 
 
7.25 
CR7 
 
7.31 
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CR8 
 
7.32 
CR9 
 
7.36 
CR10 
 
7.3 
CR11 
 
7.08 
CR12 
 
7.29 
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CR13 
 
7.31 
CR14 
 
7.37 
CR15 
 
7.32 
CR16 
 
7.4 
CR17 
 
7.25 
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CR18 
 
7.31 
CR19 
 
7.32 
CR20 
 
7.36 
CR21 
 
7.29 
CR22 
 
7.08 
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Table 8. Synthetic Accessibility predicted indexes for the compounds of the initial library 
 
As reported in table 8 the compounds initially designed show a relatively low synthetic accessibility, being the 
predicted index for all the molecules > 7, in a scale from 0 (easy) to 10 (difficult). 
In a second step of the work, other simpler structures were added to the initial library looking for a higher 
synthetic feasibility. This purpose was achieved by considering structures with simpler R1 substituent. Indeed, 
the newly designed compounds, in fact, show lower predicted synthetic accessibility indexes, as shown in 
table 9.   
 
Compound Structure Synthetic Accessibility 
CR24 
 
6.56 
CR25 
 
6.1 
CR23 
 
7.31 
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CR26 
 
6.57 
CR27 
 
6.89 
CR28 
 
6.07 
CR29 
 
6.07 
CR30 
 
5.48 
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Table 9. Synthetic Accessibility predicted indexes for the compounds added at the initial library. 
 
As we can observe from table 9 the predicted index of synthetic accessibility computed for some of the new 
compounds is about 6 (CR25, CR28, CR29) or <6 (CR30). The newly designed compounds were also 
subjected to the molecular docking screening in analogous manner with respect to the ones belonging to of 
the initial library. The molecular docking results of these new ligands in the Cathepsin L binding site are 
reported in table 10. 
 
Table 10. Results referring to the best scoring compounds. For the evaluation of the best scoring compounds intermolecular hydrogen bonds and 
interaction energies (Ebind) were taken into account. The distance (D) to CYS25 residue was also reported. 
 
One of the compounds showing a quite good result is CR29. The best pose identified by Autodock for this 
ligand shows its optimal accommodation in the Cathepsin L binding site. The ligand shows a very good spatial 
complementarity to the protein within the binding site, with a distance (3.2 Å) between one of the two C atom 
of the ligand ring and the protein S atom of CYS25 compatible with the auspicate covalent bond formation. 
 
 
 
 
 
 
 
 
Figure 11. Best pose of CR 29  in the cathepsin L binding poket. 
 
Comp. Ebind (Kcal/mol) D [Å] Hydrogen Bonds 
CR24 -10.09 4.7 / 
CR25 -10.59 5.7 Cys25 
CR26 -11.34 4.5 Asp162 
CR27 -11.15 5.4 Asp162 
CR28 -10.1 5.4 Asp162 
CR29 -9.38 3.2 / 
CR30 -7.28 4.8 Cys25 Asp162 
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In order to get a deeper insight in the interaction between inhibitors and the biomolecular target of interest, 
three compounds which appeared of particular interest were subjected to MD simulations. Two of them had 
given the most interesting results from molecular docking. CR26 shows the lowest energy. CR 29 shows the 
lowest distance from CYS25. The third one (CR 30) was selected since it shows a particularly simple structure 
(predicted index of synthetic accessibility: 5.48). The results of Molecular Dynamic simulations are shown in 
Figures 12 (CR26), 13 (CR29) and 14 (CR30).  
In particular, we monitored the trend of the distances between the two C atoms of  the aziridine group and the 
S atom of CYS25 of the protein during the simulation time in order to evaluate if a covalent bond would occur 
for these ligands. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. The trend of the two distances (Å) between two carbon atoms of the aziridine group and the sulfur atom of cysteine 25 are monitored 
during the simulation time.  The best pose of CR26 in the binding site.  The distance between the closer C atom of the aziridine group and the sulfur 
atom of cysteine 25 was highlighted. 
 
As we can observe from figure 12, the two interatomic distances monitored during all the simulation maintain 
distances out of the a range compatible with the formation of a covalent bond. Indeed  the distances are ever > 
3.5 Å so probably CR26 ligand could not approach the CYS25 in the correct manner to form the auspicate 
bond.  
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Figure 13. The trend of the two distances (Å) between two carbon atoms of the aziridine group and the sulfur atom of cysteine 25 are monitored 
during the simulation time.  The best pose of CR29 in the binding site. The distance between the closer C atom of the aziridine group and the sulfur 
atom of cysteine 25 was highlighted. 
 
We can observe from figure 13 that one of the two monitored distances (distance 2) spends a quite significant 
amount of time in a range compatible with the formation of a covalent bond. We can infer that CR29 ligand 
could approach the CYS25 residue in the correct manner to form the auspicate bond. In figure is also reported 
the frame corresponding to the lower d2 distance (3.159 Å).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. The trend of the two distances (Å) between two carbon atoms of the aziridine group and the sulfur atom of cysteine 25 are monitored 
during the simulation time.  The best pose of CR30 in the binding site. The distance between the closer C atom of the aziridine group and the sulfur 
atom of cysteine 25 was highlighted. 
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We can observe from figure 14 that the two distances monitored during all the simulation stay much over a 
range compatible with the formation of a covalent bond, in fact they are ever > 4-4.5 Å. Probably CR30, like 
the CR26 ligand, can not approach the CYS25 in the correct manner to form the auspicate bond.  From all the 
performed simulations (molecular docking and dynamics) and considering the predicted synthetic accessibility, 
the CR29 ligand seems to be the most promising ligand. 
 
5.2.2 Commercial Ligands 
In order to speed up the discovery of new inhibitors, bypassing the delay on experimental validation entailed 
by synthetic issues, already available commercial ligands were searched using similarity criteria with respect to 
the aziridine ring and different portions of the nucleus shown in figure 2 chapter 4. The structure of these 
compounds were reported in table 4 chapter 4. This search was afforded within ChemID Plus Advanced server 
(http://chem.sis.nlm.nih.gov/chemidplus/) in which it is possible to look for many different compounds 
characterized by a certain level of similarity with regard to pre-selected structures (in our case, the aziridine 
ring and different portions of the nucleus shown in figure 3).  The search carried out by using a similarity 
threshold of 50 % enabled the identification of about 20 compounds, the structires of which were retrieved by 
the database. Among them the E-64 compound is included. It is a well known irreversible, potent and highly 
selective cysteine protease inhibitor. Indeed E-64 does not react with the functional thiol group of L-lactate 
dehydrogenase or creatine  kinase, non-protease enzymes[1-2]. E-64 does not inhibit serine proteases (except 
trypsin) like the cysteine protease inhibitors, leupeptin and antipain[3-4]. It does not react with low molecular 
weight thiol compounds such as 2-mercaptoethanol.  E-64 has been used as an active site titrant[5-3-6]. The 
trans-epoxysuccinyl group (active moiety) of E-64 irreversibly binds to an active thiol group of many cysteine 
proteases such as papain, actinidase, and cathepsins B, H and L[4-7] to form a thioether linkage. E-64 is a very 
useful cysteine  protease inhibitor for use in vivo studies because it has a  specific inhibition, it is permeable in 
cells and tissues, it  has low toxicity, it is easily synthesized and it is stable[4]. The crystal structure of a 
complex between papain and a synthetic analog of E-64 (E64c) was reported. 
 
CAS number Ebind (Kcal/mol) D [Å] Hydrogen Bonds 
66701-25-5 (E64) -5.10 3.1 
Gln19 
Cys25 
Glu63 
Asn66 
Gly68 
76684-89-4 (E64c) -5.22 3.3 Gly68 
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Gln19 
88321-09-9 (E64d) -5.53 3.3 
Gln19 
Asp162 
4114-28-7 -3.51 - Gln19 Cys25 Asp162 His163 
16466-61-8 -4.48 - Gly68 
17696-94-5 -4.9 - Gly68 Asp162 
21384-57-6 -5.86 4.5 
Gln19 Cys25 
Trp189 
84315-89-9 -6.5 3.5 Gln19 Cys25 
 
Table 11.  Results referring to the commercial  compounds. For the evaluation of the best scoring compounds interrmolecular hydrogen bonds 
and interaction energies (Ebind) were taken into account. The distance (D) to CYS25 residue was also reported. 
 
 
The best pose selected by Autodock for the E64c inhibitor in the Cathepsin  L binding site is very similar to the 
pose taken by E64c in the crystal structure  when co-crystallized in the papain binding site (PDB ID: 1PPP) as 
showed in Figure 15 and 16.  
In particular the distances between the two C atoms of the ring in the trans-epoxysuccinyl group (active 
moiety) and the S atom of the catalytic CYS 25 in Cathepsin L are significantly compatible with the formation 
of the covalent bond. The same distance experimentally measured for the complex E64c-papain are stricter 
because the two partners are already covalently bond as reported in Figure 15 and 16.  
 
 
 
 
 
 
 
 
 
 
Figure 15. Best pose selected by autodock for E64c in the Cathepsin L binding site. 
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Figure 16. Crystallographic pose of E64c in papain binding site. 
 
The poses taken by E64c in the two binding sites are very similar to each other so confirming once again that 
the Autodock program is able to identify a pose of E64c in Chatepsin L which correctly reflects the biological 
condition. 
 
5.2.3 Aziridine Derivatives 
Simpler aziridine derivatives already available thanks to a collaboration with Prof Pineschi at Department of 
Pharmaceutical Science, and structurally similar to the template used in our design work were added to the 
docking screening for the search of other potential “hit” molecules to be used  in the search for effective 
Cathepsin L inhibitors. 
In this case, the docking analysis was performed in more depth, analyzing the best pose for each cluster 
identified by Autodock. Indeed the previous work only implied the analysis of the best pose of the first cluster. 
This because these simple molecules are expected to supply just “hits” to be subsequently optimized. 
Because of that, the analysis of all the possible orientations and conformations could contribute at suggesting 
structural changes enabling us to optimize the structures and make them suitable for improving the interaction 
with the target. 
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Number of pose 
for each cluster 
Ebind (Kcal/mol)  
(1° pose for each 
cluster) 
H bond  
(1° pose for each cluster) 
Distances  
(1° pose for 
each cluster) 
 
az1 
c1: 99 -3.69 - 5.8/7.0 
c2: 1 -3.5 - 9.0/8.7 
 
az2 
c1: 59 -6.51 TRP189 7.7 /7.6 
c2: 4 -6.22 - 4.9/5.5 
c3: 12 -6.17 GLY68 5.5/7.0 
c4: 18 -5.83 
CYS25 
GLN19 
4.3/4.5 
c5: 1 -5.79 TRP189 3.9/4.6 
c6: 2 -5.6 - 8.2/7.7 
c7: 1 -5.48 - 3.5/4.8 
c8: 3 -5.45 
TRP189 
GLN19 
5.3/6.6 
 
az3 
c1: 37 -6.73 GLY68 7.7/7.2 
c2: 60 -6.7 TRP189 7.1/8.0 
c3: 1 -6.31 GLN19 4.7/5.7 
c4: 2 -5.24 GLN21 8.2/9.4 
 
az4 
c1: 32 -6.97 
TRP189 
GLN19 
7.0/7.9 
c2: 52 -6.59 GLY68 7.6/7.2 
c3: 6 -5.98 GLN21 9.7/8.3 
c4: 8 -5.78 - 3.3/3.6 
c5: 1 -4.99 GLY68 7.3/7.6 
c6: 1 -4.95 GLN19 5.6/4.5 
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az5 
c1: 82 -6.22 TRP189 7.7/7.6 
c2: 6 -5.72 GLY68 5.6/7.1 
c3: 3 -5.67 CYS25 4.8/5.5 
c4: 2 -5.39 - 5.1/4.7 
c5: 7 -5.11 
TRP189 
GLN19 
5.1/5.8 
 
az6 
c1: 1 -2.1 ASN18  12.4/13.6 
c2: 18 -1.87 GLN21 10.5/11.6 
c3: 10 -1.79 GLN21 11.7/12.8 
c4: 24 -1.76 - 4.2/4.0 
c5: 1 -1.76 - 9.1/8.2 
c6: 31 -1.67 - 7.0/7.6 
c7: 11 -1.65 - 9.6/9.5 
c8: 1 -1.64 - 9.3/10.4 
c9: 1 -1.6 - 7.0/6.1 
 
az7 
c1: 60 -7.19 GLY68 6.9/7.5 
c2: 20 -6.92 TRP189 8.2/7.3 
c3: 8 -6.81 - 4.7/4.5 
c4: 5 -6.66 - 8/7.5 
c5: 5 -6.51 - 6.4/7.2 
c6: 2 -5.87 - 9.6/9.3 
 
az8 
c1: 99 -4.51 - 5.8/7.1 
c2: 1 -3.7 - 8.8/8.8 
 
az9 
c1: 49 -1.59 - 13.3/12.5 
c2: 49 -1.56 - 14/13.7 
c3: 1 -1.53 - 16.2/16.0 
c4: 1 -1.46 GLN21 12.2/10.8 
 
az10 c1: 51 -4.68 GLY68 4.7/5.5 
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CYS25 
c2: 49 -4.36 
TRP189 
GLN19 
5.9/5.3 
 
az11 
c1: 20 -2.7 GLN21 9.6/10.5 
c2: 1 -2.59 GLN21 8.3/9.2 
c3: 68 -2.53 - 9.6/9.7 
c4: 7 -2.42 - 4.7/5.6 
c5: 4 -2.38 - 6.8/7.9 
 
az12 
c1: 82 -3.2 - 4.6/5.4 
c2: 9 -3.16 GLN21 9.7/10.3 
c3: 9 -2.95 - 8.4/7.0 
 
az13 
c1: 97 -2.51 - 5.5/6.6 
c2: 3 -2.23 - 10.2/9.1 
 
az14 c1: 100 -3.78 - 5.9/7.0 
 
az15 
c1: 68 -1.94 - 4.5/3.7 
c2: 4 -1.87 GLN21 8.4/9.4 
c3: 11 -1.75 - 12.7/11.9 
c4: 7 -1.73 - 11.4/12.2 
c5: 10 -1.72 - 7.0/5.8 
 
Table 12. The number of poses (of 100) for each energetic cluster was reported for each analyzed compound. Moreover, for the first pose of each 
cluster, the binding energy, the H bonds and the distances between the two reactive C atoms of the ligand ring and the protein CYS25 S atom were 
reported. 
 
The observation of data reported in table 12 suggests that this screening didn’t afford encouraging results. 
Almost all the poses selected for these ligands appeared to be poorly allocated in the binding site. In the 
ligands the critical C atoms of the ring are often very far from the S atom of the CYS25 residue in the target 
protein. The sole ligand that could have some chance of interacting with Cathepsin L is az4, for which 
Autodock selected some poses where the required distance are quite good for the interaction.  
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Az4 was initially investigated in one of its four diastereisomer forms. Due to its potential interest, its three other 
forms were also investigated. The results are reported in table 13. 
 
 Number of 
pose for each 
cluster 
Ebind (Kcal/mol)  
(1° pose for each 
cluster) 
H bond  
(1° pose for each cluster) 
Distances  
(1° pose for 
each cluster) 
 
az4_cis 
c1: 45 -7.05 TRP189 7.5/8.1 
c2: 34 -6.84 GLY68 7.5/7.2 
c3: 5 -5.94 - 6.4/5.5 
c4: 2 -5.89 CYS25 3.6/4.0 
c5: 5 -5.78 GLN21 7.8/6.8 
c6: 1 -5.66 - 10.4/10.4 
c7: 5 -5.63 - 7.8/8.5 
c8: 1 -5.44 - 9.1/7.7 
c9: 2 -5.43 GLY68 7.4/7.3 
 
az4_cis2 
c1: 16 -6.37 GLN19 6.7/6.5 
c2: 22 -6.12 GLY68 8.0/8.0 
c3: 4 -5.93 GLN21 9.6/10.9 
c4: 26 -5.73 GLY68 6.9/7.1 
c5: 18 -5.67 TRP189 8.3/7.8 
c6: 10 -5.31 - 4.0/5.4 
c7: 1 -5.3 CYS25 4.0/3.4 
c8: 1 -5.29 - 4.0/4.1 
c9: 1 -5.15 - 6.7/7.5 
c10: 1 -4.86 TRP189 9.1/9.6 
 
az4_trans2 
c1: 50 -6.64 TRP189 7.3/7.2 
c2: 28 -6.19 GLY68 8.3/8.3 
c3: 16 -6.14 GLY68 7.0/6.5 
c4: 6 -5.66 GLY68 7.2/7.4 
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Table 13. The number of poses (of 100) for each energetic cluster was reported for each analyzed compound. Moreover, for the first pose of each 
cluster, the binding energy, the H bonds and the distances between the two reactive C atoms of the ligand ring and the protein CYS25 S atom were 
reported. 
 
The results obtained for the other three stereoisomers of az4 were not as good as the first isomer analyzed. 
Because of that we came back to consider only the first isomer and, starting from the best pose of cluster 4 
found for az4 (figure 17), we tried to suggest some modification in order to increase the possibility of 
interaction with Cathepsin L.  
 
 
 
 
 
 
 
 
 
 
Figure 17. the best pose of cluster 4 found for az4. The arrow shows the para- position of the phenil ring directly attached to the aziridine ring 
were some substituents were added. 
 
In particular, we tried to add some substituents in the para- position of the phenil ring directly attached to the 
aziridine ring. The substituents to be tried in such a position were: -OMe, -OH, -CH3, -F, -Br, -I, -Cl, CF3. The 
new molecules added to the entire pool for virtual screening are the ones labelled as reported below: 
az4_OMe, az4_OH, az4_Me, az4_F, az4_Br, az4_I, az4_Cl, az4_CF3. 
The results obtained for this last group of new molecules are reported in table 14: 
 
 Number of 
pose for each 
cluster 
Ebind (Kcal/mol)  
(1° pose for each 
cluster) 
H bond  
(1° pose for each 
cluster) 
Distances  
(1° pose for each 
cluster) 
 
az4_Br 
c1: 35 -7.54 
TRP189 
GLN19 
7.0/7.9 
c2: 7 -7.4 GLY68 7.1/6.7 
c3: 2 -6.73 GLN19 6.4/5.5 
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c4: 22 -6.41 - 3.4/3.6 
c5: 21 -6.28 GLY68 7.4/7.4 
c6: 3 -6.27 GLY68 5.4/6.5 
c7: 1 -5.99 TRP189 5.1/5.7 
c8: 1 -5.79 GLY68 7.5/7.3 
c9: 2 -5.75 - 8.4/7.1 
c10: 5 -5.73 - 6.6/6.9 
c11: 1 -5.21 - 8.9/9.3 
 
az4_CF3 
c1: 16 -7.03 
TRP189 
GLN19 
7.0/7.9 
c2: 3 -6.98 GLY68 7.4/7.0 
c3: 10 -6.34 GLN19 6.2/5.3 
c4: 24 -5.92 GLY68 7.5/7.4 
c5: 2 -5.88 TRP189 6.9/5.5 
c6: 7 -5.86 GLY68 5.5/6.6 
c7: 13 -5.74 
TRP189 
GLN19 
7.7/7.4 
c8: 9 -5.63 GLY68 6.0/4.6 
c9: 6 -5.63 - 3.7/3.5 
c10: 1 -5.46 GLN21 8.2/9.5 
c11: 1  -5.4 TRP189 5.2/6.0 
c12: 3 -5.15 GLN19 5.7/4.3 
c13: 1 -5.13 TRP189 4.3/4.4 
c14: 3 -5.0 - 6.6/6.9 
c15: 1 -4.97 GLY68 7.1/7.2 
 
az4_Cl 
c1: 27 -7.43 TRP189 7.1/8.0 
c2: 3 -7.18 GLY68 7.3/6.9 
c3: 5 -6.7 GLN19 6.3/5.4 
c4: 2 -6.53 CYS25 5.1/5.8 
c5: 4 -6.31 GLN21 9.6/8.3 
c6: 30 -6.21 - 3.3/3.6 
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c7: 16 -6.17 GLY68 7.4/7.4 
c8: 1 -5.93 - 4.9/5.1 
c9: 2 -5.8 TRP189 6.1/5.1 
c10: 1 -5.75 GLY68 7.2/7.3 
c11: 2 -5.57 - 6.8/8.2 
c12: 6 -5.56 - 7.5/6.1 
 
az4_F 
c1: 41 -7.02 TRP189 7.1/8.0 
c2: 1 -6.73 GLY68 7.5/7.1 
c3: 13 -6.01 GLY68 6.3/5.2 
c4: 9 -5.87 - 7.1/7.2 
c5: 1 -5.83 GLN21 9.7/8.4 
c6: 3 -5.77 TRP189 6.3/5.2 
c7: 15 -5.74 GLY68 4.3/4.7 
c8: 7 -5.72 - 3.4/3.6 
c9: 8 -5.71 GLY68 7.2/7.3 
c10: 1 -5.43 TRP189 5.4/4.7 
c11: 1 -5.10 - 7.7/8.5 
 
az4_I 
c1: 41 -7.76 
TRP189 
GLN19 
7.0/8.0 
c2: 1 -7.26 GLY68 7.1/6.8 
c3: 3 -6.99 GLN19 6.3/5.3 
c4: 19 -6.65 - 3.4/3.6 
c5: 1 -6.64 GLN21 9.7/8.4 
c6: 16 -6.42 GLY68 7.4/7.4 
c7: 2 -6.19 - 5.1/5.3 
c8: 5 -6.08 GLY68 7.4/7.3 
c9: 3 -6.08 - 8.2/6.8 
c10: 7 -6.07 - 6.6/6.9 
c11: 1 -5.92 - 11.1/10.7 
c12: 1 -5.83 GLN19 6.1/4.7 
 
Chapter 5 
 
Page 98 
 
az4_Me 
c1: 41 -7.35 TRP189 7.1/8.0 
c2: 13 -7.29 GLY68 7.4/7.0 
c3: 3 -6.64 GLN19 6.2/5.3 
c4: 1 -6.49 CYS25 5.0/5.6 
c5: 2 -6.44 GLN21 9.7/8.3 
c6: 13 -6.14 - 3.3/3.6 
c7: 15 -6.02 GLY68 7.4/7.4 
c8: 4 -5.92 TRP189 5.1/6.2 
c9: 1 -5.79 - 7.5/7.5 
c10: 5 -5.57 - 7.3/6.0 
c11: 1 -5.51 - 7.1/7.4 
c12: 1 -5.26 GLY68 4.6/5.1 
 
az4_OMe 
c1: 38 -7.12 
TRP189 
GLN19 
7.8/6.9 
c2: 4 -6.98 GLY68 6.2/5.5 
c3: 12 -6.0 GLY68 4.9/4.5 
c4: 1 -5.93 GLN21 9.5/8.2 
c5: 24 -5.84 - 3.3/3.6 
c6: 10 -5.64 GLY68 7.2/7.4 
c7: 2 -5.61 CYS25 6.7/7.1 
c8: 6 -5.51 CYS65 7.2/5.9 
c9: 1 -5.5 TRP189 6.2/5.4 
c10: 1 -5.4 GLN21 4.2/5.6 
c11: 1  -5.3 CYS25 7.8/8.6 
 
az4_OH 
c1: 8 -6.93 GLY68 7.8/7.3 
c2: 32 -6.79 
TRP189 
GLN19 
7.0/7.9 
c3: 13 -6.74 GLY68 5.4/6.1 
c4: 9 -6.37 
GLY68 
CYS65 
6.4/5.3 
c5: 18 -6.17 GLY68 7.4/7.4 
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MET161 
c6: 5  -6.03 
TRP189 
GLN21 
6.3/5.2 
c7: 3 -5.75 ASP162 7.5/6.0 
c8: 2  -5.53 - 7.2/7.3 
c9: 1 -5.48 GLN21 9.6/8.3 
c10: 2 -5.45 ASP162 4.2/4.1 
c11: 1 -5.44 CYS25 7.3/6.9 
c12: 3 -5.38 - 3.3/3.7 
c13: 1 -5.31 GLY68 4.5/4.9 
c14: 1 -5.15 GLY68 7.5/7.3 
c15: 1 -4.76 ASP162 7.0/7.1 
 
Table 14. The number of poses (of 100) for each energetic cluster was reported for each analyzed compound. Moreover, for the first pose of each 
cluster, the binding energy, the H bonds and the distances between the two reactive C atoms of the ligand ring and the protein CYS25 S atom were 
reported. 
 
We can summarize the content of the above table as follows: the sole molecule of the first screening that show 
some chances to interact with Cathepsin L is az4. The first pose of its 4° cluster (the third most populated 
cluster) shows an interaction energy of -5.78 kcal/mol , and the two distances of interest of  3.3 and 3.6.  
Starting from az4, some modified molecules gave a little increase of the results, in particular:  
 
- az4_I. The first pose of its 4° cluster (the second most populated cluster) shows an interaction energy of -
6.65 kcal/mol, and the two distances of interest of  3.4 and 3.6 Å 
- az4_Br. The first pose of its 4° cluster (the second most populated cluster) shows an interaction energy of -
6.41 kcal/mol, and the two distances of interest of  3.4 and 3.6 Å 
- az4_Cl.  The first pose of its 6° cluster (the first most populated cluster) shows an interaction energy of -6.21 
kcal/mol, and the two distances of interest of  3.3 and 3.6 Å 
- az4_Me.  The first pose of its 6° cluster (the forth most populated cluster) shows an interaction energy of -
6.14 kcal/mol, and the two distances of interest of  3.3 and 3.6 Å 
- az4_OMe. The first pose of its 5° cluster (the second most populated cluster) shows an interaction energy of 
-5.84 kcal/mol, and the two distances of interest of  3.3 and 3.6 Å 
 
while other modified compounds led to results less interesting:  
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- az4_F.  The first pose of its 8° cluster (the sixth most populated cluster) shows an interaction energy of -5.72 
kcal/mol, and the two distances of interest of  3.4 and 3.6 Å 
- az4_CF3. The first pose of its 9° cluster (the seventh most populated cluster) shows an interaction energy of 
-5.63 kcal/mol, and the two distances of interest of  3.7 and 3.5 Å 
- az4_OH.  The first pose of its 12° cluster (the eightieth most populated cluster) shows an interaction energy 
of -5.38 kcal/mol, and the two distances of interest of  3.3 and 3.7 Å 
 
So these derivatives show much less interesting capability to interact with cathepsin L binding site with respect 
to the designed ligand of the CR series. Nevertheless other attempts of optimization could be tried to increase 
this possibility. 
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CHAPTER 6 
 
ENZYME KINETICS STUDIES ON 
29 kDa HUMAN LIVER CATHEPSIN L  
              
 
                    
 
Kinetics studies carried out on 29 kDa human liver Cathepsin L take the major part of this chapter. The need of 
analyzing in depth the kinetics of this form of the enzyme is due to the observations listed below: 
- This enzyme form it is the one corresponding to the samples commercially avaliable for inhibition 
experiments; 
- Up to recent times the action of Cathepsin L was thought to be accomplished only intracellularly; 
- More recently Cathepsin L extracellular actions, important for targeting it in view of new anticancer-
antimetastatic therapies, are recognized to be accomplisgìhed extracellualrly, i.e. in an environment 
where the pH is higher and different species may be present. It implies the possibility that different 
environmental conditions significantly affect the catalytic action of Cathepsin L. 
Because of that, an investigation on the enzyme kinetics, where experimental conditions were widely changed, 
was considered worth of being accomplished in order to better understand the catalytic potential of the 
enzyme in different biological environments 
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6.1   Motivation of the study 
Several different active forms of Cathepsin L are produced by cellular processing of Cathepsin L1 preprotein, a 
37 kDa protein made up of 333 aminoacid residues (GenBank # NP_666023). Such processing embraces 
reduction and oxidation steps. Some of the different active forms of Cathepsin L are known and are 
summerized as follows: 
- a 29 kDa form, comprising two subunits: a 25 kDa heavy chain precursor and a 5 kDa light chain, linked 
together by disulfide bonds; 
- a 25 kDa form, comprising two subunits: a 20 kDa heavy chain and a 5 kDa light chain, linked together by 
disulfide bonds; 
- a 25 kDa heavy chain precursor; 
- a 20 kDa heavy chain [1,2,3,4] . 
 
From a structural point of view, the aminoacid sequences of the following forms of the protein are known: 
- the Cathepsin L1 preprotein, made up of 333 aminoacids; 
- the 5 kDa light chain, made up of 42 aminoacids which correspond to the aa range 292-333 of the Cathepsin 
L1 preprotein (GenBank # NP_666023); 
- the 20 kDa heavy chain, made up of 175 aminoacids which correspond to the aa range 114-298 of the 
Cathepsin L1 preprotein (GenBank # NP_666023) (see SwissProt database, http://www.uniprot.org , query: 
P07711). 
However, no data are known about the aminoacid sequence of the 25 kDa heavy chain precursor, the 
commercially available form. The aminoacid sequence of the 29 kDa active form in unknown as well (see 
SwissProt database, http://www.uniprot.org , query: P07711). 
Among various forms of Cathepsin L, the one derived from human liver, supplied by Calbiochem Merk (Merck 
Chemicals Ltd., Nottingham, UK) is the most commonly employed by researchers in the biological experiments 
aimed at identifying and characterizing new compounds acting as modulators of the enzyme activity. Indeed 
the scientific literature affords many papers, which refer to such a form as the one exploited in experiments, as 
resulted from a bibliografic search in the Scirus database (http://www.scirus.com/) by entering “human liver 
cathepsin L” and “Calbiochem” as the keywords. 
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Human Liver Cathepsin L supplied by Calbiochem is a ~29 kDa form, when analyzed in SDS-PAGE under 
non-reducing conditions. However, when such a protein is subjected to a reduction reaction, for example by 
treatment with cysteine, the presence of two bands can be observed in SDS-PAGE, at ~25 kDa and ~5 kDa. 
The protein purification procedure carried out by Calbiochem consists of a conventional chromatography, not 
involving affinity chromatography nor the use of reducing agents. Further procedural details are proprietary 
data owned by Calbiochem and can not be disclosed (this information was provided by Calbiochem on 
request). 
The data concerning the behavior of Human Liver Cathepsin L supplied by Calbiochem under SDS-PAGE 
conditions are in agreement with other literature data dealing with the purification of the human liver enzyme. 
The cleavage of the 29 kDa protein by reducing agents into two shorter proteins of ~25 and ~5 kDa, results 
from the reduction of disulfide bridges linking two different protein subunits [5] . Calbiochem declares that the 
aminoacid sequence of Human Liver Cathepsin L corresponds to aa. 114-333 of Cathepsin L1 preprotein 
(GenBank # NP_666023). However, according to this statement, a remarkable difference of about 4 kDa 
between the molecular weight experimentally obtained by the SDS-PAGE analysis of the 29 kDa form and the 
molecular weight theoretically computable starting from the individual weigths of each aminoacid in the range 
114-333 of the 25 kDa form of the protein. In spite of the aminoacid sequence declared by the supplier, the 29 
kDa form of Human Liver Cathepsin L probably represents an intermediate enzyme form that can be produced 
by digestion of Cathepsin L1 preprotein, comprising two subunits: a 25 kDa heavy chain precursor and a 5 
kDa light chain, linked by disulfide bridges [6,4] . 
Cysteine cathepsins are generally known to primarily cleave their substrates under reducing and acidic 
conditions within endo-lysosomes. However, different authors who studied different processing conditions and 
purification protocols demonstrated that the resulting Cathepsin may show different stability and enzyme 
activity profile. For example, studies carried out in cell systems showed that Cathepsin L can be active even at 
neutral pH values under oxidizing conditions [7] . On another side, the catalytic activity of 29 kDa Human Liver 
Cathepsin L is reported to be unstable at neutral pH values [5] . Moreover, when Cathepsin L is expressed in 
Escherichia coli (E. coli) and processed to its active form as a recombinant enzyme, the stability of such a 
recombinant enzyme is decreased relative to the human enzyme, and its pH optimum was shifted to a higher 
value [6] . 
All these observations lead to the hypothesis that different protein purification procedures may affect the 
stability and activity of the enzyme. Indeed, in our experiments we have surprisingly found that Human Liver 
Cathepsin L supplied by Calbiochem is stable and still catalytically active at the pH value of 7.4 under non-
reducing conditions mimicking the environment of an extracellular compartment, as reported in more detail 
below. 
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The interest in therapeutic potentialities which can be exploited thanks to a proper modulation of Cathepsin L 
at an extracellular level is now  increasing. For example, the inhibition of this enzyme is believed to be able to 
reduce tumor cell invasion [8] . Further, the modulation of extracellular Cathepsin L can affect its interaction 
with extracellular matrix components, potentially leading to a series of biological responses, such as vascular 
remodeling [9] and inflammatory responses [10]. 
The experiments described in this Chapter were aimed at characterizing and understanding the behavior of 
the Human Liver Cathepsin L supplied by Calbiochem. To reach this goal, the stability and catalytic activity of 
this enzyme were investigated under different conditions, such as: 
- non-reducing conditions and pH of 7.4, in order to simulate the extracellular compartment; 
- in the presence of several metal ions, such as iron, zinc and copper; 
- in the presence of the natural modulator/inhibitor Cystatin B (Stefin B). 
Data resulting from these experiments provided interesting information which allowed us to better understand 
the potentiality of Cathepsin L in playing its roles at the extracellular level. Moreover, such data provided us 
with a good basis to draw a mechanistic model which could allow us to interpret the Cathepsin L behavior in 
different surroundings and could also allow useful tool in the experimental screening of candidate modulators 
of this enzyme. 
 
6.2.2   Cathepsin L Enzymatic Assay 
The enzymatic reaction was investigated by carrying out the assays under different conditions and by using 
different concentrations of Cathepsin L, the selected substrate Z-Phe-Arg-AMC, and several modulators such 
as the endogenous inhibitor Cystatin B, and copper, iron and zinc ions. These experiments were expected to 
help in understanding how specific environmental parameters can affect the kinetics of the enzymatic reaction. 
The general protocol for the enzymatic assay is based on the detection of the release of the fluorophore 
aminomethylcoumarin (AMC) from the Z-Phe-Arg-AMC substrate. Z-Phe-Arg-AMC (Z-Phe-Arg-7-amido-4-
methylcoumarin hydrochloride) is a fluorogenic substrate for cathepsins commonly used to easily investigate 
their enzyme activity. The fluorescent AMC moiety is linked to the remaining moiety of the substrate’s 
molecule by a peptide bond, which bond is cleaved upon enzymatic hydrolysis, and AMC release can then be 
observed and read by a fluorescent reader. The assay buffer consisted of 20 mM sodium acetate, pH 7.4, with 
changing concentrations of modulators, as detailed in the next Subsections. The enzymatic reaction was 
monitored using an Envision fluorescent microplate reader (PerkinElmer Life and Analytical Sciences, 
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Waltham, MA, USA), and the fluorescence signal was measured at the excitation and emission wavelengths of 
355 and 460 nm, respectively. 
6.3. Change of Substrate Concentration 
The effect of different substrate concentrations on the enzymatic reaction was investigated in this assay, which 
was carried out with Human Liver Cathepsin L at the concentration of 0.5 µg/ml, in 20 mM acetate buffer, pH 
7.4. Five different concentrations of the Z-Phe-Arg-AMC substrate, ranging from 0.33 to 5 µM, were used. The 
enzymatic reaction was allowed to proceed at 37°C, and fluorescence was read at several time points up to 20 
minutes. The following graph illustrates the changes in fluorescence values, as a function of time, in turn 
related to the formation of the enzyme reaction product. 
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From the curves in the graph, several interesting characteristics of the enzyme behavior can be observed. At 
increasing substrate concentrations, the enzyme reaction is faster, and also there is an increase of the 
maximum response. In particular, the curves reach a plateau, with the exception of the concentration of 5 µM, 
thus indicating that the substrate is completely processed and transformed in the product of the enzymatic 
reaction. In a classical enzymatic model 
 
the typical curve describing the formation of enzymatic reaction product as a function of time shows a trend 
consisting of a linear approximation at the beginning of the reaction followed by the “plateau”. Interestingly, in 
the case of Cathepsin L the presence of inflexion points at initial times can be observed, which may be due to 
the presence of a enzyme modulators inside the assay environment. 
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6.3.2 Change of Enzyme Concentration 
The effect of different concentrations of Cathepsin L on the enzymatic reaction was investigated in this 
experiment. Indeed, five enzyme concentrations were used, ranging from 0.03 to 0.5 µg/ml, while the 
concentration of the substrate Z-Phe-Arg-AMC was kept constant at 2.5 µM. Again, the assay buffer was 20 
mM sodium acetate, pH 7.4 and the temperature was 37°C. The progression in time of the enzyme reaction is 
illustrated in the following graph: 
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In this case, only at the enzyme concentration of 0.5 µg/ml the curve reaches a plateau. This means that at 
lower concentrations the enzyme would require longer times to be saturated by the substrate. The presence of 
an inflexion point cab ne easily observed in the curves, leading again to the consideration made above. 
Globally, as expected according to the classical model, the rate of the enzyme reaction varies according to the 
enzyme concentration: decreasing concentrations correspond to slower reactions. 
 
6.3.3 Repeated Additions of Substrate 
This experiment was carried out with two purposes: 
1) to verify that Cathepsin L is not a “suicidal enzyme”, that is an enzyme which irreversibly links to its 
substrate and looses its catalytic activity, and 
2) to verify the absence of feedback inhibition of the enzyme catalytic activity mediated by the substrate. 
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To do that, Cathepsin L at the concentration of 0.5 µg/ml was incubated in 20 mM acetate buffer, pH 7.4, at 
37°C, with the substrate Z-Phe-Arg-AMC at the concentration of 2.5 µM. Three further aliquots of the 
substrate were added, at time intervals of 20 minutes from each other. The curve of the enzyme reaction as a 
function of time, resulting from this assay, is reported in the following graph: 
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The curve in this graph shows  that Cathepsin L maintains its catalytic activity even after the addition of 
several aliquots of substrate. Inside each section of the curve referring  to a single addition, the curve tends to 
reach a “plateau”. This means that the enzyme completely converts the substrate into the product, at each 
addition. After the “plateau”, every further addition of substrate determines a resumption of the activity and the 
beginning of a new step. Among the different sections of the curve related to individual additions of substrate, 
the difference between the activity level at the “plateau” and the activity baseline for a particular fragment 
slightly tends to become thinner. This is presumably due to the overall dilution occurring every time an aliquot 
of substrate is added. 
 
6.3.4 Changes of Cystatin B Concentration 
The goal of this experiment was the evaluation of the effects of Cystatin B on the catalytic activity of Cathepsin 
L. Cystatin B (also known as Stefin B) is a protein encoded in human by the CSTB gene. It belongs to the 
family of cystatines, which embraces several proteins inhibiting the cysteine-proteases of the cathepsin 
superfamily [11] Cystatin B was used in this experiment at different concentrations. In the “Control” experiments 
cystatin B wasn’t added. Subsequent dilutions from a starting mother solution at 0,18 mg\ml were made. The 
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assay was carried out in 20 mM acetate buffer, pH 7.4, at 37°C, with the substrate Z-Phe-Arg-AMC at the 
concentration of 1.25 µM and Cathepsin L at the concentration of 0.5 µg/ml. Again, the curves are drawn in 
the graph below: 
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The curve drawn in the absence of Cystatin B (“Control”) determines the maximum catalytic activity of 
Cathepsin L as expected by virtue of its inhibitor properties. When Cystatin B is added to the assay mixture, a 
decrease in enzyme activity is observed in a concentration dependent manner. Moreover, none of the curves 
coming from the experiments wherein Cystatin B is present reaches the maximum value of activity determined 
by the enzyme alone. This indicates that the presence of the inhibitor makes the enzyme reaction slower, so 
that longer times would be required to reach maximum fluorescence intensity caused by the product. 
 
6.3.5 Change of the Concentration of Cu++, Fe++ and Zn++ metal ions 
In the scientific literature, several papers report that the biologically active group thiol is a good target for 
metal-based drugs [12] . Cathepsin L contains a cysteine residue in its active site, and metal complexes are 
supposed to inhibit such an enzyme by interacting with the -SH group of cysteine. In the present assay, the 
influence of various concentrations of the three metal ions Copper, Iron and Zinc on the catalytic activity of 
Cathepsin L was investigated. For each ion, three concentrations were selected in order to simulate different 
physiological and/or pathological states: 
1) the physiological concentration, 
2) a very high concentration, which simulates a toxicity condition, 
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3) a very low concentration, which simulates a deficiency condition. 
The enzymatic reaction was allowed to proceed in 20 mM acetate buffer, pH 7.4, at 37°C, with the substrate Z-
Phe-Arg-AMC at the concentration of 1.25 µM and Cathepsin L at the concentration of 0.5 µg/ml. The three 
following graphs represent the curves obtained for the different metal ions. 
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All the three metals at toxic concentrations determine a remarkable decrease in Cathepsin L activity, 
especially Copper and Zinc which fully block the enzyme. In the case of Cooper and Zinc both physiological 
and deficient concentrations do not seem to strongly affect Cathepsin L activity, while Iron lowers its activity at 
the concentrations 10.2 µg/ml, 102 µg/ml and 1.02 mg/ml. Interestingly, a physiological concentration of Iron 
reduces the catalytic activity of Cathepsin L by about half. 
6.4 Kinetics Studies of Extracts and Alkaloids 
6.4.1 Compound  
In base ai dati riportati in letteratura sono stati scelti 7 alcaloidi isochinolinici presenti nel Chelidonium majus: 
 Berberina 
 Protopine 
 Diidroberberine 
 Stylopine 
 Coptosine 
 Canadine 
 Cheleritrine 
Then we test this part alkaloid formed by various compounds, conditions acetate buffer pH 7.4 with addition of 
5 mM and EDTA 1 mM Cysteine temperature 37 ° C. The concentration of substrate in the assay is 1.25 uM 
and 0.5 g of protein / ml, 10-5 M concentration of the compounds prepared by the mothers of 10-2 M in the 
assay buffer. 
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As can be seen the compounds cheletrina, berberine and coptisina have good inhibitory activity against the 
enzyme. 
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6.5 Aziridine Derivatives 
The kinetic experiments were also performed on the aziridine derivatives. Only the water soluble 
compounds were subjected to the assay. All experiments were carried out at a sample concentration 
of 1% of weight 
 
 
                       
 
 
The results dindn’t show any appreciable inhibition of the assayed compounds. This is because the molecules 
tested are precursors for the compounds prepared by the docking and therefore small to be able to bind to the 
active site. 
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4. CONCLUSIONS 
Cathepsin L is an attractive target for the development of anticancer agents. In this work the design of 
inhibitors for such a target is described. Requirements for inhibition and selectivity were initially searched by 
analyzing theoretical models of Cathepsin L and the two natural protein inhibitors Stefin B (endogenous) and 
Chelidociystatin (exogenous inhibitor of vegetal origin). A pool of virtual molecules was then designed on the 
basis of SAR data obtained from the literature referring to already known irreversible inhibitors. 
All the virtual molecules generated were screened by means of molecular docking programs onto the 
Cathepsin L binding site. The complexes containing three of them were optimized and further analyzed 
through MD simulations. The CR29 ligand shows good chances to engage a covalent bond with CathepsinL 
Cys25 residue, so accounting for the inhibition action mechanism.  
Other compounds commercially available and compounds available in our lab were also screened in order to 
speed up the discovery of ligands worth to development or to speed up the identification of good lead 
compounds, characterized with good drug-likeness properties. 
Finally 6 alkaloids contained in extracts obtained from C. majus were virtually screened and then subjected to 
inhibition assays. 
Before proceeding to the inhibition assays the need for performing an exhaustive study of the kinetics of 
Cathepsin L emerged. Indeed . Cathepsin L is commonly thought to act in the intracellular compartment, but 
its importance as target for antitumor-antimetastatic agent shifts the interest to the actions which it can 
accomplish outside the cell. 
The subsequent part of the research consisted of analyzing the behavior of cathepsin L under different 
conditions, such as the ones which can be found in living organisms. One of its aims was the optimization of 
the experimental conditions to be used in assays for enzymatic inhibition, when different compartments of 
living organisms have to be simulated. 
Moreover, taking into account that Cathepsin L is responsible for different physiological processes, depending 
on its particular location, the specific conditions under which the inhibition could be studied were expected to 
help in the identification of new potential drugs acting against several different pathologies. 
The results showed that the absence of the reducing agent cysteine does not impair the enzyme activity. 
However, cysteine modulates the kinetics at the beginning of the reaction. Such an effect should be further 
investigated. 
We also observed that the enzyme activity is conserved at pH values ranging from 5.5 to 7.4, meaning that 
cathepsin L can operate at both the intracellular and the extracellular levels with comparable efficiency and it 
can be an appealing target for several different pathologies. 
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We also observed that the natural inhibitor cystatin B maintains its inhibitory activity even at pH values which 
are normally found in the e extracellular compartments. Metals appear to be able to modulate the enzyme 
activity even in the extracellular compartment as well. 
We can conclude that the results of this study point out that cathepsin L activity is compatible with the 
extracellular environment, suggesting that this enzyme may also represent an extracellular target for potential 
drugs.  
Moreover, the experiments described here suggest the importance of reproducing the proper environment, 
while screening compounds targeted at a given enzyme or receptor which is located in a given cell 
compartment. 
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